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Schwann cell (SCs) are the glia of the peripheral nervous system. During
development, a common precursor develops into two distinct types of SCs: myelinating
SCs and non-myelinating SCs. There is little literature regarding the non-myelinating
variety of SCs, specifically a type of non-myelinating SC found at the neuromuscular
junction (NMJ), the terminal Schwann cell (tSC). Terminal SCs are critical for the
maintenance and recovery of the NMJ. Peripheral nerve injury causes tSCs to become
reactive, a state characterized by changes in gene expression and the extension of cellular
processes. It is in this state, that tSCs help to restore functionality to the denervated
junction. What drives tSCs to become reactive after injury remains largely unknown.
Previously, nine zinc-finger proteins (ZFPs), a class of transcription factors, have been
implicated in SC development and differentiation. As a result, transcription factors from
the ZFP family were considered as potential candidates that may drive the activation of
tSCs. Because tSCs are few and far between, only two-six cells cover the NMJ, I used a
largely non-myelinated nerve of the autonomic system, the cervical sympathetic trunk
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(CST), to search for ZFP candidates. I created a cDNA library from both control and
denervated CST resulting in 40 unique ZFPs. Six of these genes were studied futher:
Zipro1, Zfp36, Zfp612, Zfp180, Zfp111 and Zfp629. I found a near two-fold increase in
Zipro1 mRNA and protein in denervated CST, and no change in the other five ZFPs
(results from Zfp629 remain inconclusive). Using an antibody against Zipro1, I located
this increase of Zipro1 to the SCs of the denervated CST. I also found Zipro1 expression
in tSCs and an increase of 19% in tSCs of denervated rat muscle. Upregulation of Zipro1
in non-myelinating SCs suggests that Zipro1 may have a role in the activation of tSCs.
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 CHAPTER 1:  GENERAL INTRODUCTION
Glia- the understated cells
Glia are non-neuronal cells of the nervous system, outnumbering neurons 10 to 1.
These pervasive cells have often been referred to as support cells or general care-takers,
contributing little to neural function. This notion of glia is rapidly changing as these cells
are redefined as active partners to neurons in the nervous system and not just as innocent
bystanders. There are two major classes of glia: microglia and macroglia. Microglia are a
type of macrophage, an immune cell that engulfs and destroys pathogens and intruders,
thus protecting neurons in the central nervous system. Macroglia consist of four types of
cells in the central nervous system: astrocytes, oligodendrocytes, ependymal cells, and
radial glia. Macroglia of the peripheral nervous system consists of one type of cell, the
Schwann cell (SC). Schwann cells of the peripheral nervous system appear to perform
many similar functions as astrocytes and oligodendrocytes of the central nervous system.
Therefore, it is likely that the study of SCs will have implications for how both these
types of glia behave and function in the central nervous system. 
Schwann Cells
Schwann cells (SCs), the glia of the peripheral nervous system, arise from the
neural crest during development. A common precursor cell results in two types of SCs,
myelinating and non-myelinating SCs. Myelinating SCs wrap around axons and form
myelin, a lipid-rich substance that serves as an insulating coat. Myelin allows an
electrical current to propagate down an axon with little attenuation, thus preserving the
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integrity of this signal. The production and or maintenance of the myelin sheath have
many clinical implications because many motor system disorders, such as multiple
sclerosis, stem from the dysfunction of this sheath. As a result of the high number of
myelin related disorders, most research has focused on myelinating SCs and little is
known about their non-myelinating cousins.
Non-myelinating SCs are normally associated with small caliber, sensory axons,
such as c-fibers, and are also associated with pre-synaptic axon terminals at a particular
peripheral synapse, the neuromuscular junction (NMJ). The glial cells that reside at the
NMJ are known as terminal SCs (tSCs). After peripheral nerve injury, both myelinating
and non-myelinating SCs play extremely important roles during the regeneration of the
axon at the NMJ. Both SCs and tSCs produce and release a number of crucial molecules
such as neurotrophic factors, cell-adhesion molecules (Levi et al., 1995) and cytokines
(Jander et al., 2002) that aid in the reinnervation of the synapse.
Schwann cells express different genes after denervation
In vivo, nerve injury triggers a process known as Wallerian degeneration. During
this process damaged axons and their associated myelin begin to degenerate and become
phagocytosed by SCs and macrophages distal to the site of injury. This process is
necessary in order for the synapse to begin the regeneration process (Fawcett and Keynes,
1990). After nerve injury, SCs de-differentiate, or become 'reactive', reverting to an
earlier developmental stage. These reactive SCs begin to express a different pattern of
genes. For example, changes in gene expression induce the production of the low affinity
NGF receptor. This receptor is not expressed in adult SCs but is rapidly upregulated in
SCs found in the distal stump of the axotimized nerve 36 hours post nerve injury (You et
al., 1997). Neuregulins and their receptors erbB2 and erbB3, are also upregulated in SCs
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after denervation (Carroll et al., 1997). Similarly, nestin, a type VI intermediate filament
protein, is also normally absent in a particular type of SC, the terminal SC, but becomes
abundant 3 days after axotomy (Kang et al., 2007). Changes in gene expression, along
with the release of mitogens and cytokines, enable the SCs to proliferate and speed up
neuronal regeneration that aid in the demyelination, phagocytosis and regeneration of the
axon (Carroll et al., 1997). Which molecules are responsible for changes in gene
expression after injury are still unknown, but this change in gene patterning is crucial in
order for reinnervation of the junction to occur. 
Terminal Schwann cells 
Terminal SCs (tSCs) are non-myelinating SCs that make up one component of the
tripartite NMJ. The other two components of the NMJ are the motor axon, and the
underlying muscle fiber. Terminal SCs cap the motor axon terminal, that resides directly
above the post-synaptic muscle membrane. A synaptic cleft separates the two sides.
Terminal SCs do not just support the NMJ, as was once thought. Terminal SCs play
critical roles that extend beyond that of support for this tripartite synapse (Auld and
Robitaille, 2003; Kang et al., 2003). Known roles for tSCs include the function,
maintenance, formation and plasticity of the synapse (Araque et al., 1999), although new
roles for tSCs continue to be discovered. 
Roles of terminal Schwann cells   
Terminal SCs can modulate synaptic transmission
Terminal SCs express many different types of membrane bound receptors and ion
channels. Although tSCs do not have the ability to fire action potentials, they can alter
synaptic transmission by eavesdropping on neuronal activity through these receptors. For
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example, in the frog, stimulation of the nerve terminal at the NMJ creates an increase in
intracellular calcium levels in tSCs (Jahromi et al., 1992). Receptors on tSCs appear to be
responsible for this increase in intracellular calcium as blockage of neurotransmission
from the nerve terminal prevents this increase (Robitaille et al., 1997). By monitoring
activity at the synapse, tSCs are able to directly modulate synaptic transmission. Binding
of neurotransmitters and other molecules to G-protein coupled receptors on tSCs initiates
a G-protein mediated pathway that results in a decrease in neurotransmitter release from
the pre-synaptic cell. This is thought to occur through the release of nitric oxide from the
tSC (Robitaille, 1998). Blocking receptors on tSCs, thus inhibiting the G-protein
pathway, no longer caused a decrease in the amount of transmitter released from the pre-
synaptic cell (Robitaille, 1998). Terminal SCs also have a role in buffering excess
potassium ions, resulting from an increase of neuronal activity, at the NMJ. This
buffering of potassium may be due to the tSC's cells ability to reposition potassium
channels on their membranes allowing for the removal of potassium from areas of high
concentration (Kang et al., 2003).
Terminal SCs role in NMJ maintenance
Another role for tSCs at the NMJ is in the maintenance of the synapse. Ablation
of tSCs at the adult frog NMJ has no initial effect on the survival or morphology of the
junction. However, these synapses cannot be maintained and after one week the axons
begin to retract resulting in denervation of the junction (Reddy et al., 2003). The same
results have also been shown in transgenic mice that lack all SCs. The lack of SCs,
including tSCs, is created by knocking out receptors for neuregulin, a growth factor that
is necessary for the survival of SCs in the mouse. NMJs are formed but soon thereafter
begin to disassemble, leading to extensive motorneuronal death (Lin et al., 2000).
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Together, these experiments indicate that SCs are not necessary for synaptogenesis per
se, but are required for the maintenance of the NMJ.
Terminal Schwann cells and the reinnervation process
Axonal injury creates a change in the pattern of gene expression in tSCs and also
results in a change of morphology. Under normal conditions, tSCs have short processes,
or projections, that extend from the cell. These extensions cover the nerve terminal at the
NMJ. In 1992, Reynolds and Woolf showed that after denervation these tSC processes
begin to extend away from the denervated junction, forming an elaborate network that
reaches several hundred micrometers in length. After reinnervation of the junction, these
processes retract. 
The function of these extended tSC processes was elucidated in 1995 by Son and
Thompson. It was already known that SCs were excellent substrates for axonal growth in
vitro (Bixby et al., 1988), but it was not known whether this was true in vivo. Son and
Thompson were able to visualize this process in vivo using antibodies to label axons and
reactive SCs in the denervated junction of the adult rat soleus muscle. Using fluorescent
microscopy they took images that showed regenerating axons following pre-existing,
axonless nerve sheaths, left over from previous axons, back towards denervated
endplates. Once these axons reached the endplate, some fibers continued on and grew
into the muscle. These escaped fibers followed tSC processes from other junctions that
had extended and formed bridges from one endplate to another (Fig 1.1) (Son et al.,
1996)
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Fig 1.1 Terminal Schwann cells processes form bridges linking denervated and
innervated junctions.
Fig1.1.Terminal Schwann cells processes form bridges linking
denervated and innervated junctions: (A) Depicts an axon innervating 3
separate muscle fibers. (B) Depicts transection of the axon and the
beginning of SC process extension (in blue). (C) Depicts reinnervation of
one NMJ from an axon (in red) following the old nerve sheath and
resulting in terminal sprouts that follow individual TSC process. TSC
processes have formed a bridge linking the denervated junction to the
innervated junction. (D) Depicts the reinnervation of the bottom NMJ
from the axon crossing the SC bridge and then retrogradely growing up
the old nerve sheath and then innervating the top NMJ. (Modified from
Son, Trachtenberg, & Thompson, 1996).
These images from Son and Thompson supported the idea that axons did have a
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preference for growing along tSC processes in vivo, but what remained unclear was
whether the tSC was guiding the axon or whether the axon was guiding the tSC process.
This was difficult to interpret with static pictures. In 2003, Kang and colleagues designed
a double transgenic mouse in which all components of the NMJ could be observed using
fluorescent microscopy. In this mouse, green fluorescent protein (GFP) was downstream
from regulatory sequences for S100, a SC specific marker, and cyan fluorescent protein
(CFP) was downstream of regulatory sequences for Thy-1, a neuronal-specific marker. In
this mouse, SCs were labeled with GFP, axons with CFP, and acetycholine receptors
were labeled with a non-saturating amount of rhodamine-conjugated bungarotoxin (Fig
1.2) (Kang et al., 2003). Using in vivo imaging, they showed conclusively that the axons
were indeed guided by the tSC processes and not the other way around. 
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Fig 1.2 In vivo reinnervation of two neuromuscular junctions in the murine soleus
muscle.
Fig 1.2. In vivo reinnervation of two neuromuscular junctions in the
murine soleus muscle. The top three panels show degeneration of the
nerve after 4 days. Acetycholine receptors (AChR) are stained with
rhodamine-bungarotoxin and show the former synaptic site without the
presence of the axon. Schwann cells (SCs) have extended processes
(arrows), one which has grown from the lower synaptic site in the
direction of the upper synaptic site. Arrowheads depict the old
endoneurial tube. There is no CFP-labeled axon panel at this point. After
day 10 of denervation, the old synaptic sites mostly retain their shape
(AChR). A CFP-labeled axon has sprouted from the lower junction and
has followed the old endoneurial tube up and reinnervated the upper
junction. (Modified from Kang et al., 2003).
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In summary, tSCs have more roles at the NMJ then a supporting one. Their roles
in the plasticity and maintenance of the NMJ are critical for synaptic function.
Specifically, their role in the reformation and recovery of the synapse after injury is of
clinical importance.
Zinc-finger protein transcription factors in SC development 
Most zinc-finger proteins (ZFPs) are transcription factors, proteins that regulate
and control the conversion of genetic information from DNA into RNA. The ZFP family
constitutes the largest family of transcription factors (Klug, 2005). Zinc-finger proteins
interact with DNA through their highly conserved zinc-finger domains. Each domain
consists of two antiparallel sheets, an helix, and a stabilizing zinc ion. The specific
residues that make up the helical portion of the zinc-finger determine the binding
specificity. The amino acid sequence encoding each finger is highly conserved and
consists of about thirty amino acids. The conserved consensus sequence for an individual
finger is Cys-X2-4-Cys-X3-Phe-X5-Leu-X2-His-X3-His. The structure is shown in fig
1.3.
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Fig 1.3 A cartoon representation of a zinc-finger protein motif.
Fig 1.3 A cartoon representation of a zinc-finger protein motif. The
structure consists of an helix and two antiparallel sheets. A zinc ion
(green) is crucial for the molecule's stability. Figure was modified from
original obtained from Wikipedia, author Thomas Splettstoesser.
The development of neural crest cells into SCs, and the decision concerning
whether or not they will have the ability to produce myelin, is dependent on certain
transcription factors (Jessen and Mirsky, 2002). At lease nine ZFPs have been identified
in SCs and are implicated in their development. Several of these are from a family of
immediate-early genes, the early growth response (Egr) family, and some are responsible
for changes in gene expression after injury. For example, Egr2 (Krox20) is essential in
10
determining whether a precursor SC will become a myelinating or a non-myelinating SC
(Topilko et al., 1994; Jessen and Mirsky, 2002), while Erg1 (Krox24) is expressed and
upregulated in SCs, after nerve injury (Topilko et al., 1997). Because of the pre-existing
evidence of ZFP involvement in transcriptional changes in SCs, it is likely that this class
of transcription factor has implications for the reactivation of tSCs after injury.
Cervical sympathetic trunk
Studying tSCS is a difficult endeavor. One reason for this difficulty is the lack of a
specific marker for tSCs. Both myelinating SCs and non-myelinating tSCs arise from a
common precursor; therefore they express many of the same genes. For instance, S100 is
a marker for tSCs, however it labels all types of SCs. Neuregulin-2 is expressed by tSCs
but also by motor neurons and other interneurons in the spinal cord (Rimer et al., 2004).
Other markers, such as protein zero (P0) and myelin-associated glycoprotein (MAG), are
expressed in both types of SCs as well, although their expression is weaker in tSCs
(Georgiou et al., 1994). Specific markers exist for tSCs in other model systems such as
frogs and snakes. Lectin peanut agglutinin specifically labels tSCs in frogs and snakes
(Ko and Chen, 1996), whereas a monoclonal antibody (2A12) only labels tSCs at frog
NMJs (Astrow et al., 1997). No specific marker exists for mammalian tSCs yet.
Other difficulties in studying tSCs are their scarcity and their location. There are
only two-six tSCs per NMJ and only one NMJ per muscle fiber. Uncovering patterns of
gene expression through the isolation of RNA from individual tSCs proves to be an
arduous task. The cervical sympathetic trunk (CST) is a good way to circumvent this
problem. The CST is a peripheral nerve of the autonomic system. It is composed of
inputs from spinal segments TI-T7, although 90% of axons emanate from T1-T3 (Rando
et al., 1981). TThe CST sends its afferents to the superior cervical ganglion. What makes
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the CST preparation so appealing is that it consists of bundles of mostly non-myelinated
axons. These bundles are known as Remak bundles (Aguayo, 1973). Ample material
from non-myelinating SCs can be obtained from RNA isolated from the CST, as non-
myelinating SCs are associated with these Remak bundles. It is possible that non-
myelinating SCs of the CST may not be a perfect model for tSCs. However, their
common lineage implies that they most likely share a core transcriptional program.
Rationale for this study
Understanding the molecular mechanisms that underlie non-myelinating SC
activation, specifically tSC reactivation, would directly benefit the area of research
surrounding axonal regeneration, not only in the peripheral nervous system, but also in
the central nervous system. Difficulty of isolation and a lack of markers specific to no-
myelinating SCs has prompted us to resort to using a different model, the cervical
sympathetic trunk. Transcription factors from the zinc-finger family have already been
implicated in various aspects of SC development, therefore I looked within this family of
transcription factors to find novel genes that may be behind the reactivation of tSCs after
injury.
The structure of my thesis will be as follows: Chapter two contains a manuscript,
which represents the majority of my findings for this dissertation. This manuscript is
currently in press in Neuroscience. Chapter three contains additional data and results not
included in my manuscript. Chapter four summarizes my findings and discusses future
directions and conclusions of my work. Finally, chapter five provides a detailed
methodology of my work. 
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CHAPTER 2: INDUCTION OF ZINC-FINGER PROLIFERATION 1
EXPRESSION IN NON-MYELINATING SCHWANN CELLS AFTER
DENERVATION
Abstract
Terminal Schwann cells (tSCs) are non-myelinating glia that cover the nerve
terminal at the neuromuscular junction. They are required for the maintenance of the
neuromuscular synapse and are likely to play essential roles in the restoration of synaptic
connections after nerve injury. Terminal SCs acquire a reactive phenotype after nerve
damage characterized by the extension of cellular processes that may facilitate
reinnervation. The molecular signaling events underpinning the tSC reactive state remain
elusive, in particular, little is known about transcription factors involved in the
transcriptional reprogramming during tSC activation. Prior research implicated nine
members of the zinc-finger transcription factor family in SC development and
myelination, and levels of one such protein were reported increased in other
nonmyelinating SCs after denervation. We hypothesize that zinc-finger transcription
factors could play a role during tSC activation. Because of their relative paucity, tSCs are
difficult to study molecularly. Here, we used the rat cervical sympathetic trunk (CST), an
autonomic nerve in which non-myelinating SCs are the predominant cell type, to isolate
zinc-finger protein (ZFP) cDNAs by RT-PCR. We isolated 29 unique ZFP sequences of
which zinc proliferation 1 (Zipro1) was the most abundant. We found that after CST
transection, levels for Zipro1 mRNA doubled and that Zipro1 protein expression
increased in non-myelinating CST SCs. We also determined that Zipro 1 is expressed in
tSCs and its levels increased following skeletal muscle denervation. Thus, Zipro1 is a
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good candidate for a transcription factor involved in activation of non-myelinating SCs in
general, and tSCs in particular.
Introduction
Schwann cells (SCs) are the glia of the peripheral nervous system. During
development, the neural crest gives rise to two distinct types of SCs, one that produces
myelin and one that does not (Jessen and Mirsky, 2002). Given their importance in
myelin generation, and perhaps because of the associated human demyelinating
neuropathies, much of the work on SCs has focused on the myelinating cells, whereas
much less is known about the non-myelinating SCs. Specifically, little is known about a
type of non-myelinating SC at the neuromuscular junction (NMJ), the terminal Schwann
cell (tSC). These cells are required for NMJ maintenance (Reddy et al., 2003). In
addition, tSCs likely play an essential role in re-establishment of synaptic connections
following nerve injury in adult animals (Kang et al., 2003). Denervation induces dramatic
changes in tSC gene expression and morphology. These “reactive” tSCs change their
gene expression (Kang et al., 2007) and generate de novo cellular processes, which
provide a favorable substrate for the incoming nerve to reform connections at the original
synaptic sites during regeneration. The molecular mechanisms underlying the tSC
reactive state remain elusive largely because of the paucity of specific molecular markers
associated with this process. In particular, little is known about transcription factors that
may be involved in the transcriptional reprogramming that takes place upon tSC
activation.
The zinc-finger protein (ZFP) family is the largest family of transcription factors
14
in the mammalian genome (Klug, 2005). Previous research has implicated at least nine
members of this family in SC development and myelination (Alonso et al., 2004). One
zinc-finger transcription factor in particular, Egr-1 (also known as Krox24), was found
upregulated in non-myelinating SCs after denervation (Topilko et al., 1997). Thus, it is
reasonable to hypothesize that transcription factors belonging to this family could also be
involved in the phenotypic changes during tSC activation. Terminal SCs are difficult to
study biochemically as their numbers per muscle are very low. There are only 2-6 tSCs
per NMJ, one NMJ per muscle fiber. Most relevant in this context is the fact that a NMJ
represents only 0.1% of the muscle surface. Hence, once a muscle is homogenized, the
fraction of tSC-specific RNAs and/or proteins is very low. One way to circumvent this
limitation is to use a preparation in which non-myelinating SCs, similar to tSCs, represent
the predominant cell type. Such a preparation is provided by the cervical sympathetic
trunk (CST) (Aguayo et al., 1976), an unmyelinated preganglionic trunk of the superior
cervical ganglion. 
Here, we used degenerate primers to the conserved C2H2 motif in zinc-finger
transcription factors to isolate ZFPs cDNAs from the CST in the adult rat by RT-PCR.
We generated a library of partial cDNAs encoding 29 unique ZFPs. The cDNA for zinc-
finger proliferation 1 (Zipro1, also known as RU49, ZFP38) (Chowdhury et al.,
1992);(Yang et al., 1996) was the most abundant sequence in our library. Thus, we next
studied the expression and regulation by innervation of Zipro1 in the CST. We found that
Zipro1 mRNA was increased after denervation of the CST. This increase appeared
selective as mRNA levels for another gene highly represented in our library, zinc finger
protein 36 (Zfp36) was unchanged. Using a previously uncharacterized, commercial
antibody against Zipro1, we found by Western blot analysis that Zipro1 protein was also
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increased after CST denervation. Immunocytochemical staining with the same antibody
showed that Zipro1 is present in SCs and neurons in the CST, but that the increase in
protein levels after denervation was limited to the SCs and not the neurons. Lastly, tSCs
stained for Zipro1 and also showed an increase of such staining after skeletal muscle
denervation. Thus, Zipro1 is a good candidate for a transcription factor gene involved in
activation of non-myelinating SCs in general, and tSCs in particular.   
Materials and methods
Animal Surgeries
All surgical procedures and animal care followed institutional and NIH
guidelines. For CST: adult male and female Sprague-Dawley rats (95-215 g) were
anesthetized by intraperitoneal injection of Nembutol® Sodium Solution (62 mg/kg). A
ventral mid-cervical incision was made and the cervical sympathetic trunk (CST) was
transected at a distance of 2–3 cm caudal to the superior cervical ganglion (SCG).
Following surgery, animals were allowed to recover for 3 or 4 days. Successful surgeries
were demonstrated by ipsilateral ptosis. Animals were then sacrificed by CO2 inhalation
and both denervated and intact CSTs were harvested and frozen in liquid N2. The
segment of the transected CST removed for analysis was between the lesion and the
SCG. For muscle: murine leg muscles were denervated by cutting the sciatic nerve under
anesthesia. An injection of a 75 mg/ml ketamine, 5 mg/ml xylazine mixture was
administered i.p. for every 100 g in weight. Animals were sacrificed 3–4 days after
denervation, and muscles were removed and processed as described below.
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Tissue culture and transfection
The SC line D6P2T (Bansal and Pfieffer 1987) and the human embryonic
carcinoma 293T cells were grown in DMEM with 10% FBS and 50 g/ml gentamycin.
Reverse transcriptase-polymerase chain reaction (RT-PCR) and Isolation of a Zinc 
Finger Motif-enriched cDNA Library
CSTs were harvested as above. Total RNA was prepared with RNA
STAT-60 reagent according to the manufacturer’s instructions (Tel-
Test, Friendswood, TX). SuperScript II reverse transcriptase (Invitrogen, Carlsbad,
CA) was used to make cDNA from 500 ng of RNA per sample, and 1/10th of the reaction
was used for PCR with HotStart PCR Master Mix (Qiagen, San Diego, CA). The
following degenerate primers were used for isolation of ZFPs: CysX2
5' -TGCCCNGAGTGYGGNAAR-3' and H/C 5' -NGGCTTCTCNCCNGTATG-
3'. Cycling parameters were 15 min at 95°C, 1 initial cycle for 3 min at 94 °C, followed
by 40 cycles for 1 min at 94 °C, 1 min at 48 °C and 1 min at 72 °C, and a final extension
for 10 min at 72 °C. (Alonso et al., 2004). Samples were run in 2% agarose gels.
Amplified bands were isolated using Qiaex (Qiagen, San Diego, CA) and directly
subcloned into the pCR2.1-vector (TA cloning kit, Invitrogen, Carlsbad, CA) to generate
a zinc finger motif enriched cDNA library. Individual clones were randomly selected and
their identity was confirmed by DNA sequencing.  
Semi-quantitative PCR
Semi-quantitative PCR was done by collecting aliquots from PCR reactions at
different cycles during amplification. The collected samples were run on a 1% agarose
17
gel containing ethidium bromide and an image was captured. Average grey values of the
bands were quantified using Metamorph 5.0 (Universal Imaging). The results were
graphed with the log of average grey values vs. linear cycle numbers. Differences in
mRNA values were obtained using linear regression from equations obtained from lines
fit to the data points. Primer sequences were: Zipro1: Forward 5'- AGT CCC AGG TTT
GGA GTG TG-3'; Reverse 5'-GAA GGT CCC AAC TGT AA-3'. Zfp36: Forward 5'-
CCC TGT TGG ACT CCA CCT AA-3'; Reverse 5'-GCC TCT TCT CCA CTG TCA
GG-3'. -actin: Forward 5'-GCT ACA GCT TCA CCA CCA CA-3'; Reverse 5'-AAG
GAA GGC TGG AAA AGA GC-3. Cycling parameters were 95°C for 15 min, 39 times
at 94°C for 1 min, 50°C for 30 s and 72°C for 30 s, followed by a final extension at 72°C
for 10 min.  
 Western Blotting
Cerebellum, kidney, liver, skeletal muscle, and both transected and control CSTs,
were removed from rats and snap frozen in liquid N2. Cerebellum, kidney and liver were
homogenized with a polytron in a ice-cold RIPA buffer with 10% v/v Protease Inhibitor
cocktail (Sigma, St. Louis, MO). CSTs were homogenized by sonication in the same
buffer. The extracts were passed through a 21-gauge needle several times to reduce
viscosity and stored at -80°C until use. D6P2T and 293T cells were cultured as above,
rinsed in cold PBS, and scraped from the dish in RIPA buffer with 10% v/v Protease
Inhibitor cocktail (Sigma, St. Louis, MO); cells were broken up by passage of the
suspension through a 21-gauge needle several times. Samples were spun down for 10 min
at 1000g at 4°C. Supernatants were concentrated using a Centricon YM-30, 30,000 MW
cut-off (Millipore Corp., Bedford, MA), following the manufacturer's instructions.
Protein concentration was estimated using Bradford-based, Biorad Protein Assay (Biorad,
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Hercules, CA). The indicated amount of each extract was mixed with 2x Laemmli sample
buffer (Sigma, St. Louis, MO), heated for 5 min at 95°C, and fractionated in 7.5%
acrylamide denaturing gels and transferred to PVDF membranes. Western blots were
blocked with 5% non-fat milk in TBS-T and probed with Zipro1 antibody, used at 1/350
dilution. Horseradish Peroxidase-conjugated anti-rabbit secondary antibody (Jackson
Immunoresearch, West Grove, PA) was used at 1/3000 dilution. Antibody-binding was
detected by chemiluminescence according to the manufacturer’s instructions (Perkin
Elmer). For normalization, membranes were stripped, blocked and re-probed with a
monoclonal antibody to -tubulin (T-9026; Sigma, St. Louis, MO), used at 1/4000
dilution and Horseradish Peroxidase-conjugated anti-mouse secondary at 1/4000 (Jackson
Immunoresearch, West Grove, PA). For quantification, film was scanned and images
were saved as TIFF files. Optical
density measurements were taken from scans of films using MetaMorph 5.0 software
(Universal Imaging). The value for denervated CST was divided by the value for the
control CST for both Zipro1 and -tubulin. For normalization, the ratio obtained for
Zipro1 was then divided by the ratio for -tubulin.
Antibodies and immunohistochemistry
Antibodies used were as follows: polyclonal antibody raised in rabbit against the
peptide sequence SNLTKHRRTHTGEKPY of Zipro1 (ZFP38/RU49) (PA1-17222;
Affinty BioReagents, Golden, CO) used at 1:250- 1:5000 dilution. A monoclonal
antibody to SV2, used at 1:200 (Developmental Studies Hybridoma Bank, University of
Iowa), and a monoclonal antibody to neurofilament (NF), used at 1:250 (2H3;
Developmental Studies Hybridoma Bank, University of Iowa) was used to mark neurons.
A rat anti-mouse antibody to CD68 (MCA19578; Serotec), to mark macrophages, was
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used at 1:50. A polyclonal rabbit antibody to S100 (Z0311, Dako), used at 1:400, and
anti-glial fibrillary acidic protein (GFAP; G3893; Sigma, St. Louis, MO) used at 1:200.
Secondary antibodies included goat anti-rabbit rhodamine-conjugated secondary antibody
(111-025-144, Jackson Immunoresearch, West Grove, PA) at 1:400 dilution. Fluorescein
or Alexa-647 -bungarotoxin (B-35450, Molecular Probes, Eugene, OR), used at 1:400
to mark AChRs, was added for the last 20 minutes during the 1 hr incubation period and
DAPI(D-1306, Molecular Probes, Eugene,OR) was added for the last 5 min to label cell
nuclei at 1:1000. 
Frozen sections of unfixed CST, skeletal muscle, and brain were stained as
described previously (Rimer et al. 1998). Whole mount staining was performed as
follows. Soleus, gastrocnemius and tibialis muscles were removed and pinned on a
Sylgaard dish with steel insect pins. They were then fixed in 4% paraformaldehyde (PFA)
for 30 min, washed 3 times for 10 min in PBS, then 1 time for 10 min in PBS-T. The
muscles were teased apart and then blocked for 30 min in blocking solution (0.5% Triton-
X100, 2% BSA in PBS). They were then incubated with primary antibody in blocking
solution overnight at room temp. The next day they were washed 3 times for 20 min in
blocking solution then incubated in secondary antibody for 1 hr at room temp. Junctional
regions were visualized with fluorescein- or Alexa-647- -bungarotoxin in blocking
solution for 45 min to mark AChRs. DAPI was added in the last 5 min of staining to label
cell nuclei. They were then washed 3 times 20 min in blocking solution, overnight at 4°C
in PBS-T and then stored in PBS. For quantification we used a 1:5000 dilution of the
Zipro1 antibody and with Metamorph 5.0 (Universal Imaging) imaging software we
measured average grey values of labeled cells. Values were averaged for cells from both




A Zipro1 probe was prepared from primers consisting of a clamp sequence, a core
promoter and the gene specific sequence. For the antisense probe the clamp sequence was
5'- CAGAGATGCA-3', a T3 core promoter 5'- ATTAACCCTCACTAAAGGGAGA-3'
and gene specific sequence of 5' -CCTTCGCCCATTAAAGTTGA-3'. For the sense
strand, clamp region was 5' -CCAAGCCTTC-3', T7 promoter 5'-
TAATACGACTCACTATAGGGAGA-3' and gene specific sequence 5'-
TTTTGAGTCCACCTGCATGA-3'. Amplification parameters were: 95°C for 15 min, 3
times at 94°C, 52°C for 2 min, and 72°C for 1.5min, 36 times at 94°C for 1 min, 62°C for
1 min and 72°C for 1.5 min followed by a final extension of 72°C for 5 min). The probe
was labeled with digoxigenin (Rimer et al. 2004) and chemically hydrolyzed (Schaeren-
Wiemers and Gerfin-Moser 1993). Rat CST and Cb were removed and snap frozen in
liquid N2. In situ hybridization was performed on 12 m cross sections following a
protocol from (Braissant and Wahli 1998) with some modifications. Hybridization was
carried out at 52°C for 48 hours. One hour wash in 2 x SSC was carried out at 61°C.
Results
Isolating cDNAs for zinc finger proteins (ZFPs) in CST  
Zinc-finger transcription factors share a highly conserved C2H2 motif with a
consensus sequence (Tyr/Phe)-X-Cys-Xm-Cys-X3-Phe-X5-Leu-X2-His-Xo-His-Xn (m
is 2 or 4; n is often 5; o is 3 or 4; X is a variable amino acid). This zinc-finger motif
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consists of around 23 amino acids with about 7-8 amino acids linking each finger (Alonso
et al., 2004). Degenerate primers were designed from this highly conserved sequence
(Alonso et al., 2004) and were used to amplify ZFPs in cDNA prepared from total RNA
isolated from CST. This product was then run on an agarose gel revealing a ladder of
bands, where each band is represented by partial ZFP sequences containing a certain
number of C2H2 zinc-finger motifs. We cut five of the bands, representing sequences
with 2-6 zinc-finger motifs, from the gel and subcloned the purified DNA. We selected a
total of 60 colonies for sequencing, and using data base analysis, we compared our
sequences against known sequences resulting in a library containing 29 unique ZFP
genes, many uncharacterized. All of the clones contained a zinc-finger motif and lacked
intronic sequences. A complete list of these genes is given in table 1. We failed to detect
sequences for Egr-1. Out of the 60 colonies sequenced, several genes appeared multiple
times. These included Zfp36, which occurred 3 times, and zinc-finger proliferation 1
(Zipro1), which occurred 8 times. As non-myelinating Schwann cells are the predominant
cell type in the CST (Aguayo et al., 1976), we reasoned that these most abundant
sequences in our library were most likely expressed by these cells. Thus, this prompted us
to study them further. 
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Table1:Zinc-finger library prepared from control adult rat CST
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Zipro1 mRNA selectively increased after denervation of the CST
We sought to determine whether Zfp36 and/or Zipro1 expression was altered by
denervation. We transected the CST unilaterally, just caudal to the SCG, in adult rats and
then after 3 days removed the nerves from both the denervated and contralateral side. The
denervated and control nerves were pooled separately. Total RNA was isolated from
these pools and RT-PCR was performed to generate cDNA. We designed primers for
Zfp36 and Zipro1 to look for differential expression in control and denervated CST
cDNA. For PCR quantification, we first amplified Zfp36 and Zipro1 in both normal and
denervated CST using as template 3 separate dilutions of cDNA (1/5, 1/25, 1/625) in an
end-point PCR reaction. There was no difference in band intensity at the highest dilution
in both control and denervated CST for Zfp36, whereas for Zipro1 the highest dilution in
the denervated sample showed a much more intense band (Fig 2.1A). At this dilution, it
was more likely that the end-point PCR reaction reflected true differences in initial RNA
levels between the samples. To quantify the difference in mRNA levels more precisely,
we used semi-quantitative PCR where aliquots of DNA were removed at specific cycle
numbers during the linear phase of amplification. A house keeping gene, -actin, was
also run at the same time for normalization purposes. The collected samples were run on
an agarose gel and an image was captured allowing us to measure the average grey values
of the bands. Quantification was done using Metamorph imaging software and the results
were graphed with the log of average grey values vs. linear cycle numbers. Using linear
regression from equations obtained from lines fit to the data points, we were able to
compare differences in mRNA levels between control and denervated CST for Zfp36,
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Zipro1 and -actin (Fig 2.1B-D). After normalizing to -actin, nearly a two-fold increase
was seen for Zipro1 in denervated CST relative to control (Fig 2.1E). No difference was
seen in Zfp36. Thus, Zipro1 expression is selectively stimulated in denervated CST. 
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Fig 2.1 Semi-quantitative PCR shows selective induction of Zipro1 mRNA in denervated
CST.
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Figure 2.1. Semi-quantitative PCR shows selective induction of Zipro1
mRNA in denervated CST. (A) Total RNA was prepared from 3-day
denervated CST and contralateral control. One microgram of each sample
was reverse transcribed and the resulting cDNA was diluted 1:5, 1:25 and
1:625. Endpoint PCR reactions were carried out with gene-specific
primers for Zipro1 and Zfp36. Amplified products were run at the same
time on 2% agarose gels containing ethidium bromide. Note that at the
highest dilution (1:625), where amplification is likely linear, band
intensity for Zipro1 is higher for denervated samples, while it is similar
between normal and denervated samples for Zfp36. M: 100-bp size
markers. (B-E) Semi-quantitative PCR was done by collecting aliquots
from PCR reactions at different cycles during amplification. Average gray
value for each band was determined and plotted vs. cycle number.
Exponential fit of the data shows that amplification for each gene was in
the linear range. Equations in top left of each panel correspond to
denervated (Den) samples, while equations in bottom right of each panel
correspond to normal (Cont) samples (B-D). To estimate expression
changes, the equations were used with the following cycle number (x
value): Zipro1, 31; Zfp36, 32; -actin, 27. (E) Den/Cont ratios were
normalized to -actin values for each zinc-finger gene; n=3. * = p < 0.05,
t-test Zipro1 vs. Zfp36.
Characterization of an anti-Zipro1 antibody
We obtained a commercial antibody said to recognize the amino acid sequence
SNLTKHRRTHTGEKPY of Zipro1. This sequence is outside the zinc-finger motifs.
Without any published literature on the antibody, we first tested it to see if we could
detect Zipro1 protein in cerebellum, a tissue previously shown to abundantly express
Zipro1 by Northern blot and in situ hybridization (Yang et al., 1996). As negative control,
we looked at tissues previously shown not to express Zipro1 by Northern analysis of total
RNA (Yang et al., 1996). We ran a Western blot, loading equal amounts of total protein
from homogenized cerebellum, liver, kidney and muscle. After probing the blot with the
Zipro1 antibody, bands at the expected molecular weight of about 63 kDa were seen in all
of samples. As anticipated, the band was strongest for cerebellum and much fainter for
the other tissues (Fig 2.2A). A few other bands were also seen in cerebellum, one higher
and two lower than Zipro1. Although the larger band, only seen in the cerebellum,
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appeared too big to be encoded by Zipro1, the smaller molecular weight bands could be
due to protein degradation. We also detected a moderately strong 63 kDa Zipro1 band in
a human embryonic kidney cell line, 293T, and using end-point RT-PCR, we found
Zipro1 mRNA in two separate mouse muscle cell lines, C2C12 and Sol8 (data not
shown). Yang and colleagues (Yang et al., 1996) published in situ hybridization data
showing strong expression of Zipro1 in the internal granular layer of the cerebellum and
other granule cells in adult rat brain. We confirmed this finding by performing non-
radioactive in situ hybridizations in the cerebellum with a probe designed against the
non-zinc-finger region of Zipro1 (Fig 2.2B). However, we also detected Zipro1 mRNA
staining in larger cells along the periphery of the internal granule layer (Fig 2.2D) (at the
junction of the granular and molecular layers). These cells could either be Bergmann glia
or Purkinje cells. We then used the commercial antibody in sagittal sections of the entire
brain. Cells in the cerebellar internal granule layer were stained strongly along with the
larger Bergmann or Purkinje cells in the periphery of this layer (Fig 2.2E). A population
of cells was also stained in the molecular layer of the cerebellum (Fig 2.2C). These cells
appeared unlabelled in the in situ experiments (Fig 2.2B). Thus, the commercial antibody
appears to detect Zipro1 in both Western and immunostaining analysis. The antibody
shows specificity that, by in large, matches previous reports based on mRNA analysis,
and our own in situ experiments. The major discrepancy is that we detected weak Zipro1
expression in tissues and cells not expected to have it based on previous observations,
such as peripheral tissues (Fig 2.2A) and molecular layer cells in the cerebellum (Fig
2.2C). It is likely that this discrepancy is explained by better sensitivity of the Western
over the Northern analysis, on the one hand, and of the immunostaining over the non-
radioactive in situ on the other (see also Discussion).
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Fig 2.2  Zipro1 expression in cerebellum, liver, kidney, and muscle of the adult rat.
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Figure 2.2. Zipro1 expression in cerebellum, liver, kidney, and muscle of
the adult rat. (A) Seventy-five gs of homogenized rat cerebellum (Cb),
liver (L), kidney (K), and muscle (M) were run on a SDS-PAGE gel and
transferred to a nylon membrane and probed with an antibody to Zipro1.
Bands were visualized by chemiluminescence. The cerebellum (Cb)
shows a strong band at the correct weight of 63 kDa, whereas weaker
bands appear for L, K and M. An unknown, larger band also appears in
Cb and weakly in L. Smaller bands may represent degraded proteins. (B)
In situ hybridizations with an antisense non-radioactive probe against
Zipro1 labels the internal granule layer (IGL) of the Cb. (Controls with
sense probe were clean, data not shown). (C) Similar IGL staining of the
Cb is seen with immunocytochemistry (ICC) using the Zipro1 antibody,
however, cells in the molecular layer are also labeled. (D,E) At a higher
magnification, in situ labeling of large cells that lie along the periphery of
the IGL are seen (black arrowheads) (D). Zipro1 staining of larger cells is
also evident with ICC (white arrowheads) (E).  Scale bar: 150 m.
Zipro1 protein increased after denervation of the CST 
We next checked for Zipro1 protein levels in normal and denervated CST by
Western blotting. We denervated CSTs unilaterally in 4 animals and removed them from
2 animals after 3 days and from 2 animals after 4 days of denervation. After normalizing
to a housekeeping protein, -tubulin, there was a 2.2 fold increase in Zipro1 protein in
samples denervated for 4 days in comparison to the control (Fig 2.3). Similar results were
also seen for samples obtained three days after denervation (data not shown). Thus, like
Zipro1 mRNA, Zipro1 protein is also increased after CST denervation.
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Fig 2.3  Zipro1 protein expression increased in CST after denervation.
Figure 2.3. Zipro1 protein expression increased in CST after denervation. CSTs 
were denervated unilaterally in adult rats and removed after 4 days. Seventy five g 
of control (C) and denervated (D) homogenized CSTs were run on a SDS-PAGE gel 
and blotted with Zipro1 antibody. A more intense band at around 63 kDa is seen in 
D versus C CST. A slightly smaller band, possibly an isoform of Zipro1 (see 
discussion), is also stronger in D CST.  Seventy five g of a SC line (D6P2T) and 
Cb extracts were also run. For normalization, the blot was stripped and re-probed 
with an antibody against - tubulin. Quantification by densitometry revealed a 2.2 
fold increase in Zipro1 expression in D CST.  Similar results were observed with 3-
day denervated CST (data not shown). 
Cellular source of Zipro1 in the CST
Antibody staining of cross sections of the CST revealed two morphologically
separate cell populations. Using DAPI to co-stain nuclei, one population of Zipro1+ cells
had a small, <10 m, strongly stained nucleus while the other population had a much
larger, faintly stained nucleus around 20 m in diameter (Fig 2.4). The identity of these
cells was ascertained by double-labeling CST tissue with antibodies against SV2 and
neurofilament (NF) that recognize neurons, and antibodies against GFAP and S100 that
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recognize SCs. SV2 and NF consistently labeled cells with larger nuclei (Fig 2.4A-A’’’)
suggesting that they are neurons, while cells with smaller nuclei were associated with the
non-nuclear staining of both GFAP (Fig 2.4B-B’’’) and S100 (data not shown),
suggesting that they are SCs. Macrophage staining was also done using an antibody
against CD68. Few macrophages were seen and were located only in the endoneurial
sheath surrounding the nerve and they were all Zipro1 negative (data not shown). Thus,
both non-myelinating SCs and neurons are Zipro1+ in the CST. To further confirm the
labeling of non-myelinating SCs by the Zipro1 antibody, we performed whole-mount
immunostaining of soleus muscles from S100-GFP mice. In these mice, SCs express GFP
(Zuo et al., 2004). We found that terminal SCs, non-myelinating SCs of the
neuromuscular junction, also labeled for Zipro1 (Fig 2.5). Consistent with these data, we
also found that D6P2T cells, a prototypical Schwann cell line (Bansal and Pfeiffer, 1987),
had high expression levels of the same 63 kDa protein found in cerebellum (Fig 2.3).
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Fig 2.4  Neurons and SCs express Zipro1 in the CST. 
Figure 2.4. Neurons and SCs express Zipro1 in the CST. (A-A’’’).
Representative Zipro1 staining of large- and small-nucleus cells seen in
CST cross-sections (A). A neuronal marker (SV2) only labels the larger
cells (A’) and this overlaps with Zipro1 staining. The white arrow
represents a large cell expressing both Zipro1 and SV2 (A’’’). Differing
sizes of cell nuclei were visualized with DAPI staining (A’’). Large,
faintly labeled nuclei correspond with SV2 and Zipro1 (yellow arrow,
A’'), whereas cells with smaller nuclei (yellow arrowhead, A'') are labeled
with Zipro1 only (A). (B-B’’’). A glial marker (GFAP), that labels SC
cell bodies and processes (B’), surrounds the cell bodies of the larger
cells leaving a space between the nucleus and GFAP stain (arrowhead).
However, GFAP abuts and surrounds the nuclei of the smaller cells,
indicating that the smaller cells are the source of the GFAP (arrow, B’’’).
Scale bar: 50 m.
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Fig 2.5  Terminal SCs express Zipro1. 
Figure 2.5. Terminal SCs express Zipro1. Whole soleus muscle was
removed from a transgenic mouse that expresses GFP (green) in SCs and
labeled with Zipro1 (red) and Alexa 647- -bungarotoxin (BTX) (blue).
(A) Zipro1 labels multiple cells at and near a NMJ. Four of the cells also
double-label for GFP (D), but only two (arrow, D) are associated with
BTX, which labels ACh receptors at the NMJ (D). (B) Four cells are
labeled with GFP here, but only the two cells associated with BTX are
tSCs (arrow,D). (C) BTX labels one NMJ. (D) The overlay shows the
co-expression of GFP and Zipro1 in two tSCs (arrow) on top of BTX
staining. Two other cells also co-express GFP and Zipro1. These may be
myelinating SCs. Red staining possibly marks myonuclei. Scale bar: 50
m.
Zipro1 protein is increased in non-myelinating SCs of the denervated CST
Because Zipro1 is expressed in neurons and SCs of the CST, we determined
whether the increase seen in Zipro1 was due to changes in expression in neurons, SCs or
both. We used a dilution of the Zipro1 antibody (1:5000) that was below saturation for
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immunostaining but that still allowed visual detection of the staining in normal CST. At
this dilution, we detected an obvious difference between normal and denervated tissue in
staining intensity (Fig 2.6A-D). We next used Metamorph imaging software to quantify
the average grey value of 335 Zipro1+ SCs and 42 Zipro1+ neurons from both control
and denervated CST. A 40% increase in Zipro1 was seen in SCs in the denervated CST,
whereas there was no change in Zipro1 expression in neurons (Fig 2.6E). Although
smaller, this increase is in line with our previous findings with semi-quantitative PCR and
Western blots. The smaller increase may be due to the presence of background
fluorescence or to non-linear aspects of the immunostaining. Thus, it appears that non-
myelinating SCs account for most, if not all, the change in Zipro1 expression after
denervation in the CST.
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Fig 2.6  Zipro1 expression levels are higher in SCs of the CST. 
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Figure 2.6. Zipro1 expression levels are higher in SCs of the CST. A-D.
Cross-sections of control (Con) and denervated (Den) CST were labeled
with a non-saturating dilution (1:5000) of Zipro1 antibody. Neurons
(arrowheads in A and C) and SCs label for Zipro1 (A,C). Zipro1 staining
is brighter in SCs of the Den CST (C). Different size nuclei seen with
DAPI staining confirms the identity of SCs versus neurons (B,D). (E)
Zipro1 expression in SCs and neurons. Histogram shows average grey
values of 335 SCs and 42 neurons from control and denervated CST.
Levels were similar for neurons but were significantly different in SCs
with a 40% increase in SCs of the denervated CST, suggesting that SCs
of Den CST have a significantly higher expression of Zipro1. *, p < 0.05,
t-test. Scale bar: 50 m.
Zipro1 protein is increased in tSCs at denervated NMJs
A prime motivation for this study was to identify transcription factor genes that
might be involved in tSC activation. Thus, we checked whether Zipro1 was also induced
in non-myelinating tSCs following skeletal muscle denervation. We used S100-GFP mice
for this experiment as it facilitated the unambiguous identification of tSCs. Using the
anti-Zipro1 antibody at 1:5000, we detected a 19% increase in Zipro1 levels in tSCs of
denervated synaptic sites (Fig 2.7). Thus, Zipro1 expression also appeared stimulated in
tSCs after denervation.
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Fig 2.7  Zipro1 expression is higher in denervated tSCs.
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Figure 2.7. Zipro1 expression is higher in denervated tSCs. The sciatic
nerve was transected in a S100-GFP mouse and the ipsilateral and
contralateral gastrocnemius muscles removed after 3 days. Whole mount
tissue was labeled with a non-saturating dilution (1:5000) of Zipro1
antibody. (A-B’’’) Average grey values were quantified for cells labeled
with Zipro1 (arrows, A) and co-expressing GFP (arrows, A’) and
overlying BTX (A’’). Zipro1 labeling is visibly stronger in tSCs of
denervated CST. (C) Zipro1 expression in tSCs. Histogram shows
average grey values for 38 tSCs in control and denervated muscle. Values
were significantly higher by 19% in denervated tSCs suggesting an
increase in Zipro1 expression. *, p < 0.05, t-test. Scale bar: 25 m.
Discussion
The underlying drive of our research is to discover potential transcription factors
that induce tSCs to become reactive. It is in this state that these cells are able to guide
axons back to reinnervate an injured NMJ, thus restoring functionality. Using a
predominantly unmyelinated nerve, the CST, we looked for potential ZFPs that might
have a role in inducing these cells to become reactive. After denervating the CST, we
found a two-fold increase of Zipro1 mRNA and protein. We resolved which cells this
increase arose from with a previously uncharacterized antibody against Zipro1. We
determined that the increase came from the non-myelinating population of SCs in the
CST. With the same antibody, we were able to determine that tSCS also express and
upregulate Zipro1 after denervation, although the increase was smaller than seen in the
SCs of the CST. 
The CST is a nerve of the autonomic nervous system that is, for the most part,
unmyelinated (98% of unmyelinated nerve fibers (Murata et al., 1982)). While the
scarcity of tSCs makes it difficult to isolate their mRNA and protein, the CST provides
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adequate levels of mRNA and protein for standard biochemical approaches and it is
easily accessible. Here, we assumed that as tSCs and most CST SCs fail to produce
myelin and arise from common precursors, they most likely share common
transcriptional programs both normally and after denervation. Although our present
results seem to bear this assumption out, it is possible that important differences exists as
tSCs are associated with motor axons and neuromuscular synapses, while the CST SCs
are associated with autonomic axons.
Our ZFP library was built from two independent CST pools, thus, we think it is a
good representation of all ZFPs expressed in the normal CST. Nevertheless, it is still
possible that there are other C2H2 ZFP genes that escaped detection by our cloning
protocol. In particular, we were surprised not to see Egr-1 clones in the CST library.
Previously, Topilko et al. (Topilko et al., 1997) found that Egr-1 is expressed by non-
myelinating SCs and is upregulated after denervation. As mentioned above, we decided
to focus first on Zipro1 because it was the most abundant sequence in our library.
However, it is possible that other genes in this library may play more critical roles in non-
myelinating SCs. Three of these genes, ZFP111, ZFP180 and U27186, may be good
candidates to study next, as they are also expressed in oligodendrocytes (Pott U, 1995;
Pott U, 1996). 
The cDNA for Zipro1 encodes a zinc-finger transcription factor-like protein.
Zipro1’s DNA-binding to a bipartite nucleotide sequence has been shown in vitro and in
vivo (Yang et al., 1996). Transcription stimulation of a reporter induced by Zipro1 has
been demonstrated in cultured cells (Chowdhury et al., 1992). Both Zipro1 mRNA and
protein (by Western analysis) increased about 2-fold after denervation. Although this
increase might not be that impressive in absolute terms, it is all relative to what this
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means for the downstream targets of Zipro1, which at the moment remain unknown. It is
possible that a small increase in Zipro1 has a large impact on the expression of
downstream target genes. It is tempting to speculate that among these, there might be
genes previously reported to be stimulated in tSCs after denervation such as nestin (Kang
et al., 2007), GFAP (Georgiou et al., 1994), growth-associated protein-43 (Woolf et al.,
1992), and the nerve growth factor low-affinity receptor p75 (Hassan et al., 1994). Very
little is known about genes expressed by normal CST SCs, much less about those whose
expression changes after nerve injury. An increase in GFAP mRNA was found in the
SCG two days after transection of the CST (Boeshore et al., 2004). Although it was not
shown that this increase was restricted to glial cells in the SCG, it is likely to be so. This
finding suggests that GFAP levels may also increase in CST SCs after nerve injury. 
Using immunostaining with a previously uncharacterized commercial antibody,
we were able to show that there were two populations of Zipro1+ cells in the CST and
that the increase in Zipro1 occurred in cells that co-labeled with SC but not with neuronal
markers. Using the same antibody we showed that tSCs also express Zipro1 and that its
levels increased there after denervation as well. Neuronal cell bodies that extend into the
caudal segments of the rat CST have been previously reported (Bowers and Zigmond,
1981). The fact that CST neurons are Zipro1+ is not surprising as granule cells in the
cerebellum and other regions of the brain have been reported to be Zipro1+ by in situ
hybridization by others (Yang et al., 1996) and ourselves (Fig 2 and data not shown).
Several lines of evidence support the specificity of the immunostaining with the
commercial antibody used here. (i) The antibody was raised against a short peptide in the
non-zinc-finger domain of Zipro1. (ii) No other significantly similar sequences were
found when we BLASTed the epitope sequence (SNLTKHRRTHTGEKPY) in
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GeneBank (data not shown). (iii) The staining was nuclear as expected for a transcription
factor such as Zipro1. (iv) In the cerebellum, the immunostaining was strongest in the
IGL, where we found that the Zipro1 mRNA in situ signal was the strongest as well. (v)
In Western blots the strongest band was the one matching Zipro1’s expected molecular
weight (about 63 kDa). (vi) High levels of Zipro1 expression have been reported in brain
and testis by several groups (Chowdhury et al., 1992; Yang et al., 1996). However, while
Yang and co-workers failed to detect Zipro1 transcript in other peripheral tissues by
Northern analysis on total RNA, Chowdhury et al. detected weak Zipro1 expression in
these tissues by Northern analysis of polyA+ enriched RNA. Thus, it is perhaps not
surprising that we detected weak Zipro1 levels in peripheral tissues by Western analysis
(Fig 2). (vii) The antibody dilution (1/5000) used to estimate the Zipro1 staining
differences between control and denervated CST and tSC samples (Figs 6 and 7), was an
order of magnitude higher than that used for Western blotting (1/350). This not only
allowed us to work outside the saturation range of the antibody but also likely improved
the specificity of the staining. Zipro1 is by no means a non-myelinating SCs-specific
transcript. In fact, we also detected Zipro1 in myelinating SCs of intramuscular nerves,
however, Zipro1 levels decreased after denervation in these cells (data not shown). Thus,
we show here that Zipro1 expression is selectively stimulated in non-myelinating SCs
after denervation.
To our knowledge, Zipro1 is the first transcription factor reported to be induced in
tSCs after denervation. As Zipro1-/- mice are viable and fertile (Yang et al., 1999), it will
be interesting to determine whether the absence of this transcription factor alters the
response of tSCs to muscle denervation.
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CHAPTER 3: ADDITIONAL FINDINGS ON ZFPS AND NON-MYELINATING
SCHWANN CELL ACTIVATION
Chapter 2 contained results and data that were submitted to a peer-reviewed
journal. There are additional results that were not included in the manuscript and these
appear in this chapter. Some of these results support the main finding in chapter 2, that
after denervation there is selective upregulation of Zipro1 in tSCs and non-myelinating
SCs of the CST. Other results pertain to different ZFPs, besides Zipro1, that I examined. 
Increase in Zipro1 expression in CST is not due to an increase in Schwann cells or 
neuron number
After showing an increase in Zipro1 levels in denervated CST, I checked whether
this increase was due to an overall increase in the number of SCs. To do this, I stained 12
μm sections of control and denervated CST with SV2, to label neurons, and Zipro1,
which labels both neurons and SCs. I counted all cells that stained for SV2 and Zipro1
and all cells that stained for Zipro1 only. I found no significant difference in the number
of Zipro1-labeled SCs between control and transected CST (Fig 3.1). However, I did
find a significantly larger number of Zipro1-labeled neurons in control CST (Fig 3.1,
p<0.05, two-tailed t-test). An increase of Zipro-labeled neurons should, in theory,
increase overall Zipro1 levels in control CST. However, despite this, an increase in
Zipro1 levels is found in denervated and not in control CST. Thus, my measurement of
transcript levels may underestimate the activation of Zipro1 in the denervated nerves.
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Fig 3.1  Schwann cell and neuron counts in control and denervated CST.  
Fig 3.1 Schwann cell and neuron counts in control and denervated CST.
12 μm sections of control and denervated CST were stained with Zipro1,
to label SCs, and SV2 antibody, to label neurons. Three circles were
placed on top of 25 sections from control and denervated CST. All 3
circles consistently fell within the boundaries of the CST. Cells stained
for Zipro1 only and cells stained for Zipro1 and SV2 were counted within
these three circles. There is no significant difference between the
amount of Zipro1+ SCs in control versus denervated CST. There is a
significant difference between the amount of Zipro1+/SV2+ neurons.
found in CST.  *, p < 0.05, t-test. 
Zipro1 levels are not increased in myelinating SCs in murine tibialis muscle after 
denervation
The overall aim of this research was to find transcription factors unique to the
reactivation of tSCs. Using whole mount murine tibialis from a transgenic mouse that
expresses GFP in SCs, I stained for Zipro1 and quantified fluorescence intensities of
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myelinating SCs in both denervated and control muscle. I used a dilution of the Zipro1
antibody (1:5000) that was below saturation for immunostaining but still allowed for
visual detection of staining in normal muscle. I then used Metamorph imaging software
to quantify the average grey value of 83 Zipro1 positive, myelinating SCs from both
control and denervated tibialis. At this dilution, I found a slight decrease in Zipro1
expression in the myelinating SCs of the denervated tibialis. Although slight, this
difference was still significant with a p < 0.05 (Fig 3.2). Myelinating SCs were
distinguished from non-myelinating tSCs by their location. Both myelinating and tSCs
express GFP, however, GFP positive cells at a NMJ (this is determined by bungarotoxin
staining which labels AChRs at the junction) were considered tSCs. For this experiment,
only GFP positive cells not associated with bungarotoxin were evaluated. Thus, it seems
that following denervation, Zipro1 levels increase only in non-myelinating SCs, including
tSCs.
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Fig 3.2   Zipro1 expression in myelinating SCs. 
Fig 3.2. Zipro1 expression in myelinating SCs. (A-F). The sciatic nerve
was transected in a S100-GFP mouse and the ipsilateral and contralateral
gastrocnemius muscles removed after 3 days. Whole mount tissue was
labeled with a non-saturating dilution (1:5000) of Zipro1 antibody. (A-
F). Average grey values were quantified for cells labeled with Zipro1
(arrows, A & D) and co-expressing GFP (arrows, B & E) in both control
(A-C) and denervated (D-F) tibialus. Zipro1 labeling is similar in
myelinating SCs of the denervated tibialis and in control tibialus. (G).
Histogram shows average grey values for 83 myelinating SCs in both
control and denervated muscle. There is a slight, but significant, decrease
in Zipro1 expression in myelinating SCs of the denervated samples. Scale
bar: 50μm.  
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Construction of a cDNA library from denervated CST
I had previously constructed a cDNA library from control CST. I also constructed
a cDNA library from denervated CST RNA using the same procedure described in
chapter 2. Fifty colonies were selected for sequencing. A complete list of both control
and denervated genes are listed in table 2. Genes in bold appeared in both control and
denervated libraries, those in italics were found in the denervated library only.
Accessions numbers with a strike-through are records that have been recently removed by
NCBI as a result of standard genome annotation processing. Another eighteen genes were
uncovered in the denervated library, eight of these genes overlapped with the control
library. Zfp629 appeared twelve times and Zfp160 appeared 8 times suggesting that both
of these genes may be upregulated after denervation. Little is known about either of
these ZFPs other than they are able to bind DNA and affect transcription (http:/
/www.informatics.jax.org). Structurally, Zfp160 contains 18 zinc-finger domains and
one Kruppel-associated box (KRAB) domain, a transcriptional repressor. KRAB domain.
Zfp629 has 19 zinc-finger domains and is expressed in the mouse retina, and in both
central and peripheral nervous systems (Blackshaw et al., 2004).
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Table2:Zinc-finger library prepared from control and denervated adult rat CST
Table 2. Library of ZFPs from control and denervated CST. ZFPs found
in denervated library only are in italics. ZFPs whose accession number
has a strike-through are records that have been recently removed by
NCBI as a result of standard genome annotation processing.
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Preliminary semi-quantitative PCR shows no mRNA increase for Zfp180, Zfp111, 
Zfp612, and Zfp36 in denervated CST
As well as looking at Zipro1 and Zfp36 (see results from chapter 2), I also looked
at three other genes that appeared multiple times in my control CST cDNA library (Table
2.1). These genes included Zfp180, Zfp111, and Zfp612. 
We denervated the CST unilaterally in five adult rats and then after three days
removed the nerves from both the denervated and contralateral side. The denervated and
control nerves were pooled separately. Total RNA was isolated from these pools and RT-
PCR was performed to create cDNA. We designed primers for Zfp180, Zfp111 and
Zfp612 to look for differential expression in control and denervated CST cDNA. One ug
of total RNA from both control and denervated CST was reverse-transcribed to create
cDNA. For Zfp612, 1/10 of the cDNA reaction was amplified through PCR and the
samples ran on a 1% agarose gel. A picture was captured from the gel and visually
inspected. There appeared to be no upregulation of Zfp612 as the band for control and
denervated CST were similar in intensity (data not shown). For Zfp180 and Zfp111,
cDNA was amplified in both normal and denervated CST using three separate dilutions
(1/5, 1/25, 1/625) in an end-point PCR reaction. There was no difference in band
intensity at the lowest dilution in both control and denervated CST for Zfp180 (Fig 3.3 )
and for Zfp111 (data not shown). A house keeping gene, -actin, was also run at the
same time for normalization purposes (Fig 3.3). Because this preliminary end-point PCR
results showed no upregulation of these genes in denervated CST, I did not study them
further. Nevertheless, these results further support the notion of a selective increase in
Zipro1 expression after transection of the CST.
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Fig 3.3 Semi-quantitative PCR shows no upregulation of Zfp180 mRNA in denervated
CST.
Figure 3.3. Semi-quantitative PCR shows no upregulation of Zfp180
mRNA in denervated CST. (A) Total RNA was prepared from 3-day
denervated CST and contralateral control. One microgram of each sample
was reverse transcribed and the resulting cDNA was diluted 1:5, 1:25 and
1:625. Endpoint PCR reactions were carried out with gene-specific
primers for Zfp180 and -actin. Amplified products were run at the same
time on 1% agarose gels containing ethidium bromide. For the highest
dilution (1:625), where amplification is likely linear, band intensity for
Zfp180 was similar in both samples M: 100-bp size markers. (B) -actin
was also amplified in control and denervated samples at the same time as
Zfp180 at the same dilutions, 1:5, 1:25 and 1:625. Theses samples were
then run on the same gel with the previous genes as a loading control. All
bands for both control and denervated samples have similar intensities
indicating that the same amount of cDNA was loaded for both samples
52
CHAPTER 4: DISCUSSION, CONCLUSIONS AND FUTURE DIRECTIONS
Discussion
The role that reactive tSCs play in the restoration and repair of a damaged
neuromuscular junction is a critical one. However, the molecular mechanisms behind the
ability of tSCs to become reactive are not known. In fact, little is known about this rare
class of non-myelinating SCs. Several zinc-finger transcription factors (ZFPs) have been
implicated in various aspects of SC differentiation and development. Therefore, we
decided to look within this family of transcription factors for possible candidates that
might drive tSCs to become reactive. Because tSCs are few and far between and difficult
to isolate, I used another class of non-myelinating SCs as my experimental model. These
SCs are derived from the mostly non-myelinated cervical sympathetic trunk (CST).
Although these cells may not be identical to tSCs, they should share enough commonality
to uncover important molecules that are involved in the reactivation process and eventual
reinnervation of the junction.
Construction of cDNA libraries from control and denervated adult rat CST
I was able to construct a library of ZFPs from RNA extracted from both control
and denervated CST. Unilateral denervation in rat results in one experimental and one
control nerve. I was able to extract an ample amount of RNA from a pool of three-six
nerves from both control and denervated CST. Denervated CSTs were removed after
three-four days after denervation. As mentioned before, the rodent CST is a nerve of the
autonomic system that is, for the most part, unmyelinated (Aguayo, 1973). This means
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that a large proportion of RNA from this nerve would be derived from non-myelinating
SCs. 
We were able to utilize the highly conserved domain of the ZFP -- (Tyr/Phe)-X-
Cys-Xm-Cys-X3-Phe-X5-Leu-X2-His-Xo-His-Xn (m is 2 or 4; n is often 5; o is 3 or 4; X
is a variable amino acid) -- to pull out only ZFPs from cDNA, prepared from my CST
RNA pools, by using degenerate primers designed against this motif. I performed a PCR
reaction with the degenerate primers and generated DNA that was subcloned and
sequenced. I constructed a library of ZFPs from both control and denervated CST,
resulting in a total of 40 unique ZFPs. Ten sequences were unique to the denervated
library only. All sequences were from the zinc-finger family emphasizing the stringency
of the degenerate primers I used. 
Zipro1 is upregulated in denervated CST
I initially focused on ZFPs that stood out amongst my cDNA library. However,
many of the ZFPs were and remain uncharacterized. I initially chose to look at ZFPs that
were sequenced multiple times. These sequences included Zipro1, Zfp36, Zfp111, Zfp
180 and Zfp612. I also looked at Zfp629 as it appeared numerous times in the denervated
library but not at all in the control library. Using semi-quantitative PCR and after
normalizing to a housekeeping gene, ß-actin, I determined that Zipro1 was increased
nearly two-fold in denervated CST. I saw no difference in Zfp36, Zfp111, Zfp 180 and
Zfp612. I was unable to make any conclusion for Zfp629 as each time I performed semi-
quantitative PCR I got differing results. I also tried to look for differences in transcript
number for Zfp629 by using real-time PCR. Unfortunately, I could never get a set of
primers that showed amplification of Zfp629 in my samples, even though I saw strong
band from the real-time PCR product on an ethidium bromide gel. I also always saw
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Zfp629 product with regular PCR. 
I wanted to support my semi-quantitative PCR results of Zipro1 with quantitative
PCR, real-time PCR. I initially had a strong result with a four-fold increase in Zipro1 in
denervated CST after normalizing to a house-keeping gene, 18s rRNA. I saw no increase
in Zfp36, which is what I expected because of the original semi-quantitative PCR results.
This lack of upregulation of Zfp36 was important to show that there was not a general
upregulation of ZFP genes in the denervated CST. After using cDNA from a second set
of denervation experiments, I was unable to replicate the original four-fold increase I had
seen in the denervated CST sample. The results for the new samples were inconsistent.
However, the overall average remained in favor of upregulation in denervated CST, but
not in a significant manner. The results for Zfp36 remained unchanged. It is unclear why
my results changed with the second set of cDNA. It is possible that my ability to dissect
the CST from the rat had improved over time so that by the time of the second round of
experiments, the result was a cleaner prep of CST. However, I performed semi-
quantitative PCR with a second and third set of cDNA, resulting in a near two-fold
increase of Zipro1 in denervated CST, similar to results from the first set of cDNA.
I performed Western blots using a commercial Zipro1 antibody purchased from
Affinty Bioreagents. Using both control and denervated CST protein from two more
separate pools of denervated and control CSTs, I found a two- fold increase in Zipro1
protein after normalizing to -tubulin. This supports my original findings of a near two-
fold increase in Zipro1 mRNA using semi-quantitative PCR.
Zipro1 expression in rat and mouse tissues
 Previous research by Yang et al (96) used non-radioactive in situs to reveal
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expression of Zipro1 in the internal granule layer of the cerebellum and granule cells in
other areas of the brain. They also found Zipro1 expresssion in skin and were able to
produce a hair-loss phenotype with a Zipro1 over-expressing mouse (Yang, Wynder,
Doughty, & Heintz, 1999). Yang et al., using Northern blots, failed to show expression
of Zipro1 in other tissues such as liver, kidney and spleen. I performed non-radioactive in
situs using a probe I designed against Zipro1 and found expression of Zipro1 mRNA in
the internal granule layer of the cerebellum, similar to Yang et al. I also found Zipro1
staining in larger cells, possibly Bergmann glia and/or Purkinje cells, along the periphery
of the internal granule layer. I also found staining in other cells outside of the cerebellum.
These cells appeared larger than granule cells. I also looked for Zipro1 expression in SCs
in the muscle and CST using in situ hybridization. I did see what looked like Zipro1
staining in these tissues, but was never able to replicate this (data not shown). This could
have been due to the rapid deterioration of mRNA in the tissue coupled with the usage of
a non-radioactive in situ protocol as opposed to a more sensitive radioactive in situ
protocol. It could have also been due to problems with the adjustment of temperature and
incubation times during the hybridization period, although I did try multiple
combinations. 
I then looked for Zipro1 expression using the commercial Zipro1 antibody.
Looking in sagittal sections of the entire brain, cells from the internal granule layer of the
cerebellum were stained strongly along with the larger Bergmann and/or Purkinje cells in
the periphery of this layer. I also saw staining of a population of cells in the molecular
layer of the cerebellum and also in other larger, unidentified cells in other brain areas
(data not shown). Concerned about the specificity of the commercial antibody, I
performed Western blots on protein from cerebellum, a tissue shown by Yang et al. and
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myself to express Zipro1. These Western blots revealed a strong 63 kDa band,
corresponding to the size of the Zipro1 protein. I also found Zipro1 protein expression in
liver, kidney and spleen, contrary to Yang et al. results. Looking at other tissues, I found
expression in muscle and in a Schwann cell line (D6P2T). This expression was
confirmed with PCR using cDNA from D6P2T cells, two muscle lines (C2C12 & Sol8), a
kidney line (293T), and also cDNA from primary SCs. A notable characteristic of the
Zipro1 antibody is that it labels only cell nuclei. This is consistent with the location of a
transcription factor, such as Zipro1. This evidence leads me to believe that the
commercial antibody is specific for Zipro1. Differing results between our group and
Yang's group could be due to a greater sensitivity of our immunohistochemistry and
Western results compared to their Northern blots and in situs.  
Since I saw upregulation of Zipro1 in CST after denervation, I needed to show
which cells expressed Zipro1 in the CST. Using cross-sections of CST, I performed
immunohistochemistry with the Zipro1 antibody. Nuclear staining occurred in two
separate cell populations, one population with a nucleus less than <10 m in diameter,
and another population with a much larger, faintly stained nucleus around 20 m in
diameter. I was able to use two antibodies, SV2 and Neurofilament, to ascertain that the
cells with the larger, fainter nuclei were neurons. The identity of the smaller cells was
harder to ascertain, however their position overlapped with GFAP staining used to label
SCs in rat CST (Fig. 2.4) . This staining patterns suggests that these smaller cells are SCs.
The next step was to look for Zipro1 expression in terminal SCs at the
neuromuscular junction. To do this, I used both cross-sections and whole-mounts of
muscle obtained from the S100-GFP transgenic mouse. Zipro1 expression was seen in
most cells expressing GFP, including terminal SCs. Terminal SCs were identified as GFP
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expressing cells on top of neuromuscular junctions. Neuromuscular junctions were
visualized using -bungarotoxin, which labels AChRs. Because Zipro1 expression was
seen in SCs of the mostly non-myelinated CST, I expected to find Zipro1 expression in
tSCs due to their common lineage. Verifying the expression of Zipro1 in both types of
SCs strengthens the idea that the SCs from the CST are a good model for studying tSCs.
Upregulation of Zipro1 is specific to Schwann cells of the CST
It has been shown that denervation can cause SCs to proliferate (Carroll et al.,
1997). Therefore it is possible that an increase in SC numbers contributed to the increase
of Zipro1 upon denervation. I counted SCs and neurons contained within a specified area
across 25 sections of control and denervated CST. There was no difference in the
number of SCs between both groups. I did find a small, but significant, decrease in the
number of neurons in the denervated CST, this could be due to neuronal death caused by
denervation. These findings support that the overall increase in Zipro1 expression is due
to SCs, not neurons, of the denervated CST. 
Both neurons and SCs in the CST express Zipro1. Are neurons, SCs or both types
of cells contributing to the increase in Zipro1 expression in denervated CST? I found a
significant increase of 40% in Zipro1 expression only in SCs of the denervated CST. This
difference is not as high as the 200% increase seen in the semi-quantitative PCR results
or the Western blot results; however, this difference could be explained by the large
variance of background staining seen from image to image or because of the non-linear
characteristics of immunostaining. I found no difference in Zipro1 expression in neurons.
Therefore, SCs are responsible for the increase of Zipro1 expression seen in the
denervated CST. 
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Terminal Schwann cells show an increase in Zipro1 expression in whole-mount soleus 
muscle
I used the same approach above to examine changes in Zipro1 expression in tSCs.
Controls and denervated muscles from a S100-GFP mouse were stained for Zipro1 and
for AChRs to mark NMJs. I found a 19% increase in Zipro1 intensity values of tSCs in
the denervated muscle. Once again, levels may not have been as high as seen with semi-
quantitative PCR or Western blots because of large variances in background staining and
non-linear aspects of immunostaining. Interestingly, the increase in Zipro1 expression
appeared restricted to tSCs as myelinating SCs in the same muscle failed to show a
significant change in Zipro1 staining. Actually, a small decrease was seen in Zipro1
expression in myelinating SCs of the denervated muscle.
Non-myelinating SCs of the CST vs. tSCs
We chose the CST as our model for tSCs as it is mostly unmyelinated. Obtaining
RNA and protein from tSCs is difficult due to the sparseness of cells and their location. It
is likely that non-myelinating cells of the CST will share some commonality to non-
myelinating tSCs as they both descend from a common precursor. However, there is a
possibility that using non-myelinating SCs from the CST will not provide us with an
accurate description of tSCs. For instance, functions of Zipro1 in SCs of the denervated
CST may not hold true for tSCs. However, because I found a similar increase in Zipro1
expression in both non-myelinating SCs of the CST and in tSCs of the neuromuscular
junction, it is possible that Zipro1 may be playing a similar role in both types of cells.  
Future directions
My dissertation research resulted in the identification of a transcription factor,
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Zipro1, that is increased in SCs of denervated CST and muscle indicating that it may
have a role in the events that occur in SCs after injury. The next step would be to test this
hypothesis. This could be done by either over-expressing Zipro1 in culture to see if the
resulting phenotype of the transfected cells mimics that of a SC after denervation, or to
look for specific genetic markers that are known to be upregulated after denervation, such
as nestin or GFAP. I tried this by transfecting cultured 293t cells with a commercial
CMV-driven Zipro1 clone, however, for an unknown reason, the vector we purchased did
not overexpress Zipro1 (data not shown). Also, even if this had worked, the endogenous
levels of Zipro1 in the SC line we used for these experiments (D62PT) turned out to be
very high initially (Fig 2.3). Thus, it is possible that a further increase in Zipro1 afforded
by the expression vector would not have altered the phenotype of these cells. To do the
overexpression experiments one would have to find SCs with low endogenous Zipro1
levels. Another way would be to overexpress Zipro1 in vivo by creating a mouse using
the tetracycline-controlled gene expression system that allows spatial and temporal
control of gene expression in vitro and in vivo (Gossen and Bujard, 1992). 
Another way to confirm whether Zipro1 is involved in transcriptional regulation in
SCs after injury would be to knock-down its expression in SCs. This could be done in
culture using RNA interference in a SC line, such as D62PT. This particular SC line has a
constitutively active ErbB2 receptor which mimics the effects of denervation (Hayworth
et al., 2006). This could also be done in vivo by microinjecting the RNAi, or an RNAi
construct, into specific SCs in a denervated muscle. Changes in phenotype could then be
monitored. In the D6P2T line, if Zipro1 is involved, then processes should retract and
there should be downregulation of gene markers such as Nestin or GFAP. In the in vivo
model, downregulating Zipro1 with RNAi should prevent SCs from becoming reactive.
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This would also be observed through morphological changes and monitoring gene
transcription levels.
Other ZFPs found in both control and denervated libraries still may prove to be
fruitful. Especially those ZFPs found only in the denervated library. Two in particular
Zfp629 and Zfp160 appeared multiple times, suggesting that they might be upregulated
after denervation. This could be done using semi-quantitative PCR, quantitative PCR and
Western blots. In situs or immunohistochemistry could be used to determine the location
of expression. If either of these genes showed any upregulation, then overexpression or
RNAi would be the next step to see if these genes are involved in reactivation process of
SCs in denervated tissue. 
Conclusions
The goal of my research was to discover potential molecules that induce tSCs to
become reactive. It is in this state that these cells are able to guide axons back to
reinnervate an injured junction, thus retaining functionality. Using a predominantly
unmyelinated nerve, the CST, we looked for potential transcription factors, from the zinc-
finger protein family that might have a role in inducing these cells to become reactive.
After denervating the CST, we found a two-fold increase in mRNA and protein levels of
the transcription factor Zipro1, a zinc-finger protein. We resolved in which cells this
increase in Zipro1 was occurring using a previously uncharacterized antibody against
Zipro1. We determined that the increase came from the population of SCs in the CST.
With the same antibody, we were also able to determine that tSCs also express and
upregulate Zipro1 after denervation, although this increase was smaller then that seen in
the SCs of the CST. Although the upregulation of Zipro1 after denervation is small,
conducting follow up experiments with Zipro1 might begin to unravel the molecular
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process behind tSC  activation. 
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CHAPTER 5: GENERAL METHODS
Animal Surgeries
All surgical procedures and animal care followed institutional and NIH guidelines.
Adult male and female Sprague-Dawley rats (95-215 g) were anesthetized by
intraperitoneal injection of Nembutol® Sodium Solution (50mg/ml) at a dose of 62 mg/
kg. A ventral mid-cervical incision was made and the cervical sympathetic trunk (CST)
was transected at a distance of 2–3 mm caudal to the superior cervical ganglion.
Following surgery, animals were allowed to recover for 3 or 4 days. Successful surgeries
were demonstrated by ipsilateral ptosis. Animals were then sacrificed by CO2 inhalation
and both denervated and intact CSTs were harvested and frozen in liquid N2. For muscle:
murine leg muscles were denervated by cutting the sciatic nerve under anesthesia. An
injection of a 75 mg/ml ketamine, 5 mg/ml xylazine mixture was administered i.p. for
every 100 g in weight. Animals were sacrificed 3–4 days after denervation, and muscles
were removed and processed as described below.
Reverse transcriptase-polymerase chain reaction (RT-PCR)   
RNA isolation was performed using Trizol® Reagent (Cat. No. 15596-026,
Invitrogen, CA). I pooled CSTs and homogenized them in a glass homogenizer in 800 l
of Trizol. The homogenized tissue was left for 5 min at room temp before the addition of
160 μl of chloroform. I then shook the sample vigorously for 15 sec and then incubated it
for 2-3 min at room temp. The sample was then centrifuged for 15 min at 12K g at 4ºC. I
transferred the top phase to a new tube and mixed it with 400 μl of isopropanol and
incubated it on ice for 30 min before centrifuging for 10 min at 4ºC. The supernatant was
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removed and 800 μl of 75% EtOH was added to the RNA pellet. I briefly vortexed this
mixture before centrifugation for 5 min at 7.5Kg at 4ºC. The pellet was then dried for 5-
10 min and then resuspended in 50 μl DEPC water. I treated 500 ng of RNA with DNase
as follows: add 1 l 10x reaction buffer (Roche), 1 l DNase 1, RNase free (Cat. No. 04
716 728 001, Roche), total RNA (500ng) and add DEPC H20 to 10 l.
This was incubated for 15 min at room temp before the addition of 1 l of 25 mM
EDTA. I then incubated this for 15 min at 65°C (to inactivate). I performed reverse
transcriptase PCR on the DNased treated RNA as follows: add 1 l Oligo DT (Cat. No.
18418-012, Invitrogen), 1 l pDN6 random primer, and 1 l 10mM dNTP mix (Cat. No.
18427-013, Invitrogen). Incubate this for 5 min at 65°C. Then, on ice, add to the mixture
4 l 5x 1st strand buffer (Invitrogen), 2 l 0.1 M DTT (Invitrogen), and 1 l RNase
inhibitor (Cat. No. 15518-012, Invitrogen). I then mixed this and spun down briefly. The
mixture was then put in a 42°C water bath for 1 min before I added 1 l SuperScript II
(Cat. No. 18064-022, Invitrogen, CA). This was incubated for 50 min at 42°C and then
inactivated for 15 min at 65°C. 
Isolation of Zinc-finger motif enriched library
I used 2 l of cDNA, prepared from 500 ng of total CST RNA, and amplified it
with degenerative primers against the ZFP motif, CysX2 5' -
TGCCCNGAGTGYGGNAAR-3' and H/C 5' -NGGCTTCTCNCCNGTATG-3'. Cycling
parameters were 15 min at 95°C, 1 initial cycle for 3 min at 94 °C, followed by 40 cycles
for 1 min at 94 °C, 1 min at 48 °C and 1 min at 72 °C, and a final extension for 10 min at
72 °C. (Alonso et al., 2004). I ran the samples in 2% agarose gels and cut out amplified
bands between 200-600 bps (usually 4-5 bands were seen). I purified these bands with
Qiaex kit (Qiagen, San Diego, CA) and directly subcloned the purified DNA into the
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pCR2.1-vector (TA cloning kit, Invitrogen, Carlsbad, CA) to generate a zinc finger motif
enriched cDNA library. Cloning protocol is as follows: The amount of PCR product used
to ligate into 50 ng of pCR®2.1 vector was determined by this formula that was obtained
from Invitrogen's TA kit manual: 
X ng PCR product =    (Y bp PCR product)(50 ng pCR®2.1 vector) 
                                      (size in bp of the pCR®2.1 vector: ~3900)
[Where X ng is the amount of PCR product of Y base pairs to be ligated for a 1:1
(vector:insert) molar ratio.]
I set up each ligation reaction as follows: x l of pre-determined amount of PCR
product, 1 l 10x Ligation Buffer (provided with kit), 2 l pCR®2.1vector (25ng/ l),
and sterile water to 9 l, add 1 l T4 DNA ligase (4.0 Weiss units) (provided with kit).
The reaction was then incubated at 14°C overnight. The next day, the ligation reaction
was transformed into One Shot® TOP10 Competent Cells (Invitrogen, CA) as per
manufacturer's protocol, with a few modifications as described in the following. I
centrifuged one vial of TOP 10 cells briefly and put it on ice to thaw. Half of the
contents, 25 l, was placed in a separate tube. Each tube was used for a separate
transformation. I added 2 l of ligation mix to each tube of cells and flicked the tubes
gently to mix. These tubes were then incubated on ice for 30 min. They were then heat-
shocked in a 42° water bath for 30-45 sec and put on ice. 400 l of LB was added to
each tube and was shaken for 1 hr at 37° at 225 rpm. Of the mixture 50 μl, 100 μl and
the pellet, after I spun down the remaining liquid for 30 sec at 1000 g, was spread on X-
gal treated LB/agar plates that contained 20 μg/ml kanamaycin and 50 μg/ml ampicillin.
The plates were incubated overnight at 37ºC. Using a toothpick, I randomly selected
individual clones that did not express X-gal and placed the toothpick in 3 mls of LB + 20
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μg/ml kanamaycin and 50 μg/ml ampicillin. These tubes were incubated overnight in a
shaker at 37ºC. The next day, I purified the DNA from all tubes that showed ample
bacterial growth using QIAprep Spin Miniprep kit (Cat. No. 27106, Qiagen), following
the manufacturer's protocol. I performed a restriction digest on the cDNA from each
miniprep using Ecor1 and incubating overnight at 37ºC. Each restriction digest was set
up as follows: 3 μl cDNA, 2 μl EcoR1 buffer (New England Biolabs), 14.5 μl water and
0.5 μl Ecor1 [100,000 units/ml] (New England Biolabs). I ran the restriction digests on a
1% agarose gel with ethidium bromide. Only samples that had two bands corresponding
to the vector (3.9kb) and the insert (100-500bp) were sent to the University of Texas at
Austin DNA Sequencing Facility for sequencing. I then compared the sequences to other
highly similar sequences using NCBI BLAST.  
X-Gal treatment of LB/agar plates: 
I spread a thin layer of 2% X-GAL (Cat. No. 7240-90-6, Research Products Int.
Corp, IL) diluted in DMF (N-N' dimethyl formamide) onto the surface of pre-set LB/agar
(plus antibiotics) plates and then placed them in a 37ºC incubator for 3-4 hours or until
most of the liquid was absorbed.
Cell culture and transfections:
The SC line D6P2T (Bansal and Pfieffer 1987) and the human embryonic
carcinoma 293T cells were grown in DMEM 1x (Cat. No. 10-017-CV, Mediatech, Inc.,
VA) with 10% Fetal bovine serum (Cat. No. 100-106, BenchMark™) and 50 g/ml
gentamycin. To overexpress Zipro1, I transfected a Zipro1 clone (inserted in an
Express-1 plasmid with a CMV promoter, purchased from ATCC) into both D6P2T and
293T cells. I plated around 5 x 104/ml to 8 x 104/ml cells per 2 ml in a 35 mm culture
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dish cells and incubated overnight in a tissue culture incubator. For transfection, I added
3 μl of Fugene 6 (Cat. No. 11 814 443 001, Roche) directly to 97 μl of DMEM with care
not to touch the sides of the tubes. The tube was mixed by flicking and incubated for 5
min at room temp. I then added a total of 2 μg of cDNA (experimental: 1 μg Zipro1
clone cDNA, 1 μg pGreen Lantern GFP plasmid (Invitrogen); control: 1 μg pGreen
Lantern and 1 μg control plasmid) to this mixture and incubated it for 15-45 min at room
temp. The cells that had been incubated overnight were checked to make sure that they
were between 50-80% confluent and then fresh media was added. I added the Fugene6/
DNA mixture in a drop-wise manner into the cell media and then gently swirled the
plates to mix. The cells were then incubated for 48 hours before I fixed and stained them
for Zipro1 according to the immunohistochemistry protocol in the methods section. Cells
used to produce efficiency curves for real-time PCR and those used in Western blots were
lysed and processed according to protocols in the methods section. 
Antibodies and immunohistochemistry 
Antibodies used were as follows: polyclonal antibody raised in rabbit against the
peptide sequence SNLTKHRRTHTGEKPY of Zipro1 (ZFP38/RU49) (Cat. No.
PA1-17222; Affinty BioReagents, Golden, CO) used at 1:250- 1:5000 dilution. A
monoclonal antibody to SV2, used at 1:200 (Developmental Studies Hybridoma Bank,
University of Iowa), and a monoclonal antibody to neurofilament (NF), used at 1:250
,(DH3; Developmental Studies Hybridoma Bank, University of Iowa) was used to mark
neurons. A rat anti-mouse antibody to CD68 (Cat. No. MCA19578; Serotec), to mark
macrophages, was used at 1:50. A polyclonal rabbit antibody to S100 (Cat. No. Z0311,
Dako), used at 1:400, anti-glial fibrillary acidic protein (GFAP; Cat. No. G3893; Sigma,
St. Louis, MO); used at 1:200. Fluorescein- and Alexa-647- -bungarotoxin (Cat.
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No.B-35450), to mark AChRs, were purchased from Molecular Probes, Eugene, OR;
DAPI (Cat. No. D-1306, Molecular Probes, OR) was used to label cell nuclei at 1:1000.
Secondary antibodies included goat anti-rabbit rhodamine-conjugated secondary antibody
(Cat. No. 111-025-144, Jackson Immunoresearch, West Grove, PA at 1:400 dilution.
Fluorescein or Alexa-647 -bungarotoxin (Cat. No. B-35450), to mark AChRs, was
added for the last 20 minutes during the 1 hr incubation period and DAPI was added for
the last 2 min. 
For frozen sections: Soleus and tibialis muscles and CSTs were pinned on dental
wax with steel insect pins then frozen in isopentane cooled in liquid N2. I identified
junctional regions by staining a sample set of muscle sections using Karnovsky stain
(5mg acetylthiocholine in 6.5 mls Na Hydrogen Maleate, ph 6.0. Then add 0.5 mls 0.1 M
Na citrate, 1 ml 30mM CuSO4, 1 ml 5mM K-ferrracyanide in 1 ml H2O). I sectioned 12
m cross sections with a cryostat and then mounted them on Superfrost Plus Gold
microscope slides. I fixed the sections in 1% PFA for 5 min, rinsed in PBS twice for 5
min then rinsed again twice in PBS-T for 5 min before placement in blocker for one hr
(blocking solution: 0.5% Triton-100x, 1.5% BSA in PBS). The slides were then
incubated with primary antibody at previously mentioned dilutions overnight at 4°C. I
rinsed them twice for 10 min in PBS-T before incubating with secondary antibody in
blocking solution for 1 hr at room temperature. The junctional regions were visualized
with fluorescein- or Alexa-647- -bungarotoxin at 1:1000 in blocking solution for 45 min
to mark AChRs. I added DAPI in the last 5 min of staining at 1:1000 to label cell nuclei. I
then rinsed the slides twice for 10 min in PBS-T and twice for 5 min in PBS before
coverslipping with Vectashield (Vector Laboratories, Burlingame, CA).
For whole mount: Soleus, gastrocnemius and tibialis muscles were removed and
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pinned on a Sylgard dish with steel insect pins. They were then fixed in 4% PFA for 30
min, washed 3 times for 10 min in PBS then once for 10 min in PBS-T. I teased the
muscles apart and then blocked them for 30 min in blocking solution (0.5% Triton-100x,
2% BSA in PBS). They were then incubated on a rocker, with primary antibody in
blocking solution, overnight at room temp. The next day, I washed them 3 times for 20
min in blocking solution then incubated them in secondary antibody for 1 hr at room
temp. I visualized junctional regions with fluorescein- or Alexa-647- -bungarotoxin
used at 1:1000 in blocking solution for 45 min to mark AChRs. I added DAPI in the last
5 min of staining at 1:1000 to label cell nuclei. The muscles were then washed 3 times 20
min in blocking solution, overnight at 4°C in PBS-T and then stored in PBS.
For cell culture: 293T and D6P2T cells were cultured as described in the cell
culture section of this section. I removed the media from the cell plates before fixing in
4% PFA for 15 min. I rinsed the cells twice for 15 min in PBS and then twice for 5 min in
PBS-T before blocking for 1 hr in blocking solution ( 3% BSA in TBS-T (0.5%)). I added
the Zipro1 antibody in blocking solution, at 1:750 and incubated over night at 4°C with
agitation. The next day, I rinsed the cells in PBS-T 3 times for 10 min. The cells were
then incubated for 1 hr at room temp in Goat anti-rabbit rhodamine-conjugated secondary
antibody at 1:400 in blocking solution. The cells were then washed 2 times in PBS-T for
10 min and 2 times for 5 min in PBS before mounting in Vectashield (Vector
Laboratories, Burlingame, CA) and coverslipping. 
In situ hybridization
I prepared riboprobes from primers consisting of a clamp sequence, a core
promoter and the gene specific sequence. For Zipro1 antisense probe:
the clamp sequence was 5'-CAGAGATGCA-3', a T3 core promoter 5'
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ATTAACCCTCACTAAAGGGAGA-3' and sequence specific sequence of 5'-
CCTTCGCCCATTAAAGTTGA-3' . For Zipro1 sense strand, clamp region was 5'
CCAAGCCTTC-3', T7 promoter 5' TAATACGACTCACTATAGGGAGA-3' and gene
specific sequence 5'-TTTTGAGTCCACCTGCATGA-3'. For Zfp629 sense strand: the
clamp sequence was 5' CAGAGATGCA-3', a T3 core promoter 5'
ATTAACCCTCACTAAAGGGAGA-3' and sequence specific sequence of 5'-
TGGGAGATCCAGCTCAGAGT-3'. For Zfp629 sense strand, clamp region was 5'
CCAAGCCTTC-3', T7 promoter 5' TAATACGACTCACTATAGGGAGA-3' and gene
specific sequence 5'-CTGTTCCAGGTGGTGAAGGT-3'. Sequencing parameters were
(95°C for 15 min, 3 times at 94°C, 52°C for 2 min, and 72°C for 1.5min, 36 times at
94°C for 1 min, 62°C for 1 min and 72°C for 1.5 min followed by a final extension of
72°C for 5 min). The amplified product was run on a 1% agarose gel. I excised a band
from the gel at the correct size and purified it using a minElute PCR purification Kit (Cat.
No. 28004, Qiagen) according to manufacturers protocol. I labeled 1 g of DNA with 2 l
DIG labeling Mix (Roche), 2 l 10X transcription buffer, 1 l (20U) RNAse inhibitor and
1 l RNA-polymerase T3 or T7 to a total volume of 20 l with H2O-DEPC. This was
incubated for 1-2h at 37°C. 1 l DNAse (RNAse free) was added for 15 min at 37°C to
digest DNA template. I hydrolyzed the probe by adding 56.2 l of solution A (50 l 0.1M
DTT, 40 l 1M NaCo3, 60 l 1M Na2CO3, 350 l DEPC-H2O) and incubating at 60°C
for 45 min. The reaction was stopped by adding solution B (50 l 0.1M DTT, 100 l 1M
Na- acetate, 5 l Acetic Acid, 345 l DEPC-H2O). The probe was precipitated for 45 min
at -80°C with the addition of 13.2 ul of 4M LiCl (made in DEPC), 331 ul of 100% EtOH.
This was then spun at 4°C for 20 min at 13k g, washed in 70% EtOH (made in DEPC-
H2O), spun again at 4°C for 10 min. I then dried and resuspended the pellet in 50 ul of
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DEPC-H2O + 50 ul formamide.
Tissue preparation: Soleus and tibialis muscles and CSTs were pinned on dental
wax with steel insect pins and a thin layer of Tissue-Tek® Cat. No. 4583, CA) was put on
top before freezing in isopentane cooled in liquid N2. I sectioned 12 m cross sections
with a cryostat and mounted them on Superfrost Plus Gold microscope slides (Erie
Scientific Corp., NH). I identified junctional regions in muscle sections with a Karnovsky
stain to visualize AChesterase. I drew a ring around sections from the junctional region
with a PAP-pen to retain solutions.I then fixed these sections in 4% PFA for 20 min at
room temp, rinsed 2 x 15min in 0.1% active DEPC in 1xPBS and 15min in 5xSSC at
room temp. before pre-hybridizing for 2h at 58°C. (prehyb solution: 50% formamide,
5xSSC, 40ug/ml salmon sperm DNA). I added 500 -1000 ng of probe from sense and
antisense sequences to the prehyb solution and then added the solution to the sections.
The slides were sealed in a airtight, humid container and incubated for 48 hrs at 58°C.
After 48 hrs, the slides were washed in mailers as follows: 30 min in 2xSSC at room
temp, 1 hr in 2xSSC at 65°C. The slides were then equilibrated for 5 min in Buffer 1
(Buffer 1: pH 7.5 Tris 100mM/NaCl 150mM) before incubation with Anti-Digoxigenin-
AP (Cat. No.. 11 093 274 910, Roche) at 1:5000 in Buffer 2 (Buffer 2: Buffer1 + 0.5%
non-fat dry milk) for 2 hrs at room temp. The antibody should be spun for 2 min at 16K
g before adding to buffer. I then washed the slides in Buffer 1 2 x for 15 min, then for 5
min in Buffer 3 (Buffer 3: pH 9.5 Tris 100mM/NaCl 100mM/MgCl2 50mM -this buffer
needs to be made fresh each time, since MgCl2 will precipitate). I then set the color
reaction overnight (For 15ml Buffer 3; add 67.5ul NBT (Cat. No... 11 681 451 001;
Roche) and 52.5 mls BCIP (Cat. No... 11 681 451 001; Roche), and wrapped the mailers
in foil to keep them in the dark without agitation. The next day, I stopped the reaction for
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15min in TE (pH 8.0). The non-specific binding was removed for 15-60 min in 95%
EtOH, depending on the strength of the staining. The slides were then placed in fresh
95%, 100% and then Histo-Clear (for 1 min in each solution) before I mounted them in
Eukitt™ Mounting Media (Electron Microscopy Sciences, PA).
Semi-quantitative PCR
Semi-quantitative PCR was performed by collecting aliquots from PCR reactions
at different cycles during amplification or with end-point PCR with differing diltuions
(1:5, 1:25 & 1:625). Each 25 l PCR reaction was comprised of 12.5 l HotStarTaq DNA
Polymerase (Ca. No. 203203, Qiagen), 0.5 l of each forward and reverse primer, and 9.5
l H20. Sequencing parameters were 95°C for 15 min, 39 times at 94°C for 1 min, 50°C
for 30 sec and 72°C for 30 sec, followed by a final extension at 72°C for 10 min. I ran the
collected samples on a 1% agarose gel containing ethidium bromide, along with
exACTgene 100bp (Cat. No.. BP 257100) and 1 Kb (Cat. No.. BP2578100) DNA ladders
(Fisher BioReagents) to determine band size. I captured an image of the gel and the n
quantifed the average grey values of the bands using Metamorph 5.0 (Universal
Imaging). I graphed the results with the log of average grey values vs. linear cycle
numbers. Differences in mRNA values were obtained using linear regression from
equations obtained from lines fit to the data points. 
Primer sequences were: 
Zipro1: Forward 5'- AGT CCC AGG TTT GGA GTG TG-3'; Reverse 5'- GAA
GGT CCC AAC TGT TCC AA-3'
Zfp36: Forward 5'-CCC TGT TGG ACT CCA CCT AA-3'; Reverse 5'-GCC TCT
TCT CCA CTG TCA GG-3'
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Zfp111: Forward 5'-GCA AGG GTT TCA GTC AGA GC-3'; Reverse 5'-CTC
TGG TGG GTG TGA AGG TT-3'
Zfp612: Forward 5'-CTG TCC CCT GAA CAG AGA GC-3'; Reverse 5'-AAG
TGT GGC ATG GGA CTA GG-3'
Zfp180: Forward 5'-AAA GCC GTA CAA ATG CAA CC-3'; Reverse 5'-GAA
CGA CTT CCC ACA CTG GT-3'
Zfp105: Forward 5'- ACC CCT TGG GAG CTA CTC AT-3'; Reverse 5'-CCA
GAC AAT GGG CAG TCT TT-3'
Zfp112: Forward 5'-TCT CAG GAC TTC CCA GCA GT-3'; Reverse 5'-GAA
CTT GAA GAG CCC GTA TG-3'
Zfp239: Forward 5'- CAT GAA CGT CCG AAA TGT TG-3'; Reverse 5'- TCC
ATA GGG CAG AAC TGG AC-3'
Zfp629: Forward 5'- GGA AAG GGC TTC AAT GAT GA-3'; Reverse 5'- CCT
TTC GTG AGT GTG GGT TT-3'
-Actin: F 5'-GCT ACA GCT TCA CCA CCA CA-3'; R 5'-AAG GAA GGC
TGG AAA AGA GC-3'  
Real-time RT PCR
I only used primers that achieved efficiency values of around 90% and these
efficiency curves were created using cDNA dilutions of 50 ng/ l, 1 ng/ l, 0.1 ng/ l, 0.01
ng/ l. Each 25 l reaction was comprised of 2 l cDNA, 2x QuantiTect SYBR Green
PCR Master Mix (Qiagen), 10x QuantiTect Primer Assay (Qiagen), H20 to 25 l.
Exception: Zipro1 Primer Assay was used at 5x. For Zfp36, each 25 l reaction was
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comprised of 2 l cDNA, 2x QuantiTect SYBR Green PCR Master Mix (Qiagen), 0.75 l
of both forward and reverse primers [20 M] and 9 l H20. Primers for Zfp36 were:
Forward 5'-CTC ACG GAA CAG TGC AGA AA-3' ; Reverse 5'- GCT TCC CTT GAC
TCA GCA GT-3'. QuantiTect Primer Assay (Qiagen) catalog information for Zipro1,
GAPDH, 18s ribosomal and Zfp629 are: Zipro1 (Rn_Zipro1_1_SG QuantiTect Primer
Assay (200) QT01626009, Qiagen), GAPDH, (Rn_2_SG QuantiTect Primer Assay (200)
QT00423122, Qiagen), 18s ribosomal ( Rn_Rnr1_1_SG QuantiTect Primer Assay (200)
QT00199374, Qiagen), Zfp629 (Rn_LOC308998_1_SG QuantiTect Primer Assay (200)
QT00397439, Qiagen). I tried two separate Primer Assay sets of Zfp629 from Qiagen and
designed my own set (Forward 5'- CCT CAG CAG GAA AGT TCT GG-3'; Reverse 5'-
CTG TTC CAG GTG GTG AAG GT-3'). None of these achieved a high enough
efficiency so I did not use them. Each reaction was run on a Stratagene Mx™ QPCR
machine. Parameters were as follows: 95°C for 15 min, 35-40 cyles at 94°C for 15 sec,
50°C for 30 sec and 72°C for 30 sec.
Western Blotting
Cerebellum, kidney, liver, skeletal muscle, and both transected and control CSTs,
were removed from rats and snap frozen in liquid N2. I homogenized the cerebellum,
kidney and liver with a polytron in an ice-cold RIPA buffer with 10% v/v Protease
Inhibitor cocktail (Cat. No.. P8340, Sigma, St. Louis, MO) 3 times for 10 sec each. CSTs
were homogenized by sonication in the same buffer at medium speed, 3 times for 10 sec
each. The extracts were then passed through a 21-gauge needle several times to reduce
viscosity and stored at -80°C until use. D6P2T and 293T cells were cultured as
previously described in this methods section, rinsed in cold PBS, and scraped from the
dish in RIPA buffer with 10% v/v Protease Inhibitor cocktail (Cat. No.. P8340, Sigma, St.
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Louis, MO); the cells were broken up by passage of the suspension through a 21-gauge
needle several times. I spun the samples down for 10 min at 1000g at 4°C. The
supernatants were concentrated using a Centricon YM-30, 30,000 MW cut-off (Millipore
Corp., Bedford, MA), following the manufacturer's instructions. I estimated protein
concentration using the Bradford-based, Biorad Protein Assay (Biorad, Hercules, CA).
The indicated amount of extracts were mixed with 2x Laemmli sample buffer (Cat. No..
S3401-IVL, Sigma, St. Louis, MO), heated for 5 min at 95°C, and fractionated in 7.5%
acrylamide denaturing gels along with a Kaleidoscope Protein Standard (Cat. No..
310001997, Bio-Rad) to mark molecular weights. The running buffer for the gel was
[(for 10x solution: For 1 L add 30.3 g Trizma base ( 0.25 M), 144 g Glycine (1.92 M) and
10 g SDS (1%)]. I transferred the gel to a prepared PVDF membranes for 1 hr at 23 mV.
Preparation of PVDF membrane was as follows: 15 sec in methanol, 2 min in H20, 2 min
blotting buffer [10x Blotting buffer: 1 L 30.3 g Trizma base (0.25 M) and 144 g Glycine
(1.92 M)]. The Western blots were blocked for 1 hr in blocking solution (5% non-fat milk
in TBS-T) and probed with Zipro1 antibody, used at 1:350, in blocking overnight at 4°C
with agitation (note: to save antibody, the blot can be rolled and placed in a 50 ml
conical tube and rotated over night at 4°C. This way needs as little as 3.5 mls total ). The
next day, I washed the blot 3 times for 15 min before adding Horse Radish Peroxidase-
conjugated anti-rabbit secondary antibody (Jackson Immunoresearch, West Grove, PA),
at 1:3000 dilution, in blocking solution for 1 hr at room temp. The blot was then washed
3 times 15 min in TBS-T. Antibody-binding was detected by chemiluminescence
according to the manufacturer’s instructions (cat# NEL103, Perkin Elmer, MA) ( I place
the blot on a small piece of saran wrap, add 400 l of each solution, pick up saran wrap
and mix by slight agitation for 1 min ). The blots were then placed in a cassette with a
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BioMax Light Film (Cat. No. 1788207, Kodak) and processed. For normalization, I
stripped the membranes for 30 min at 50°C in prewarmed stripping solution (For 500ml
of stripping buffer: 3.5ml of 14.3M Beta Mecap; 50ml of 20% SDS; 31.25 1 M Tris-HCL
ph 6.8 and 415.25ml of water). I then washed the blot 3 times 5 min in TBS-T before
blocking. I then prepared the blot in the same way as described above but with a
monoclonal antibody against -tubulin (T-9026; Sigma, St. Louis, MO) at 1:4000, and a
Horse Radish Peroxidase- conjugated anti-mouse secondary at 1:4000(Jackson
Immunoresearch, West Grove, PA). For quantification, the film was scanned and images
were saved as TIFF files. Optical density measurements were taken from scans of films
using MetaMorph 5.0 software (Universal Imaging). The value for denervated CST was
divided by the value for the control CST for both Zipro1 and -tubulin. For
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